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Long term. localized continuous release of Endostatin (END) in the vicinity of tumour 
bed represents a newstralegy for neoplaslic Ireatmenl.The main reasonoflocalizat ion is 
to maximize the therapeutic outcome and at the same time to rcduce thctox icefTectson 
thc surrounding tissues due to the exposure to the angioKenesis inhibit oryefTectofEND. 
lbe main objective of this study was to design and formulate a biodegradable and 
biocompatible polymeriedevice forddivering END at 3 sustained and constant rate. and 
at a concentration within its therapeutic window by utilizing the osmotic release 
mechanism. The new device was prcparcd by mixing of END "ith osmotically active 
cxcipients and incorporate the mixture as solid particles within 3 rubbery polyermic 
matrix. lbe resuhs demonstratcd that this new device achievcd a oonSlant and sustained 
release rate for END for a certain period. 
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Chapler' . 
Over the past few decades. and wilh the development of recombinant protein 
technology. there has been "ide interest in usingthcrapeutic proteins for thctreatmentof 
viml and neoplastic diseases. Endostalin (END) is one of the powerful angiogenic 
inhibitors that has been investigated for cancer therapy. The use of END for long·tenn 
and localized delivery has bccn hindered by the lack ofadcli vcryvchiele that can release 
active END at a sustainable rate within th~ therapeutic window. The most widely used 
route of administration for protein drugs is systemical. via multiple injections. This route 
has been reponed to haye many problems. As a result. il is a highly desirable goal to 
prepare and develop a device that ean provide a persislently high dosage al a continuous 
release rate locally within the target area. with minimal systemic exposure to the systemic 
circulation. The following review of literature outlines the mechanism of action. 
physiochemical properties. pharmacokinetics and different modes of delivery of END. 
The advantages and disadvantages of delivery systems of END have been evaluated in 
order to determine the optimal method to administer Ihis polypeptide drug. The follo"'ing 
chapten describe Ihe synthesis and chamcteri7.ation of a noyel biodegradable elastomcric 
delivery system to deliver this drug with a constant and sustained release. Two 
hydrophilic drugs wcre used in the study. Pilocarpine Nitrate (PN) was used as a model 
drug as it is a pcplidomimctic. and Endostatin (END) was used as a model prolein drug. 
ChMpte r 2 .• : ndosIMt in: .:valuation or OdiHry S)'s lemJ and Koules or Administ .... lion 
Uud in Can~~r Therapy 
2.1 ABSTKACf 
Over the past two decades, Endostatin (END), onc oflhe potent angiogen~sis inhibitors 
has bccome a treatmcut fora variety of tumors and viral discases. Several T(lutcs anddclivcry 
strategies have been reported to deliver END. however. few of them have been successful in 
the reduction of side effects and the optimization of the therapeutic outcome. The mechanism 
of action. physiochemical properties. pharmacokinetics and different modes of delivery of 
END are discussed in this review. The advantalles and disadvantalles of the delivery systems of 
END havc been discussed to direct the study and determine the most appropriate method to 
administer this drull. To conclude, a lonll-tcrm. sitc locali zed delivcryand sustained release 0 f 
END are vcry imjXJrtant strategies for the delivery of this jXJlypeptide drug. 
2.2 INTRODUCI'ION 
The clinical use of anti· angiogenic agents devcloped followinllthe introduction of the 
angiOllene~is theory by Folkman in 1971. ' Many clinical studies have demonstrated them to be 
effective in the treatment of vjllll, neoplastic. and metastatic diseases. l"", Many excellent 
research papers havc reviewed their stability. immunobiological properties. amino acid 
sequence, classification and thc mechanisms by which they exert their anti·tumol1ll activities.! 
Angiogenesis is a normal process in the body, and involves the produ~tioo of new blood 
vessels from existing ones. The angiogenesis process is ~hara~terized by a number of 
chrvnological events. Prior to neQvascularization, endothelial cells exist in a ncar inert state 
with only about I in every 10.000 undergoing division at a given time." The tumoverI1lteof 
endothelial cells in~reascs up to 50-fold during the formation of a new vascular bud. 'l These 
events require the remodeling of the extracellular matrix. which can also promote angiogenesis 
by angiogenic stimulators. The extracellular matrix surrounds the vessels and gro"1h factors 
combine to promote endothclial cell migration towards the twnor mass. These endothelial ~el1s 
supply the framework for the new vessels. Endothelial cell sprouts organize into tubular 
structures and oonn<,<:t to thc vascular network.1J Generally. newly formed capillaries are 
composed of two cell types. endothelial cells and peri~ytcs. whi~h have the ~apacity to produce 
entire~apillarynetworks. 
This process is needed to provide the cells with the necessary nutrients and oxygen 
required for their sur:ival. Angiogenesis is also required whenever there is gro"1h of new 
tissues. such as during fctal dc\·clopmcnt. v.'Ound healing. and the menstrual ~ycle. Vessel 
grov.1h is normally controlled by a finely tuned balance between angiogenic inhibitors and 
stimulators."") When new capillary grov.1h is desired. the angiogenic stimulators launeh 
signals to the endothelial cells (EC) that line blood vesse ls. The activated EC will then produce 
enzymes that break down the surrounding tissue. which pennits the EC 10 proceed beyond the 
confines of the blood vessel. The EC continue to divide and dilTerentiate, until sprouling and 
new capillary branch formation is completed.'6 It is also reponed that tumor growth affects this 
equilibrium between stimulators and inhibitors to stimulate new capillary grov.th. needed for 
their nourishment to continue to grow. With aCCeSS to the circulatory system. thc tumors can 
metastasize to mherparts of the body.' 
According to the ml"Chani.m of 8<:tion, there arc two main elasses of angiogenesis 
inhibitors. designated as direct and indire.:! inhibitors." Direct inhibitors such as END and 
Angiostatin target Ee rather timn the tumor cells themselves." [n addition. they seem to 
preferentially targC1tumor Ee versus normal Ee by inhibiting the Ee proliferation. migration. 
andlUbefomlationofthctumorandinduceapoptosis'9-l'lndirectangiogcnic factors. such as 
[ntcrferon-alpha and Riba~irin, target tumor cells by pre\'enting the expression of angiogenic 
growth factors and their rcceptors.ll It has been suggested by Hanahan el al that direct 
inhibitors of angiogenesis may be subdivided imo three other subgroups,u The first group is 
the p= angiogenesis inhibitors. which inhibit the new vessel grow1h but have no effe.:t On 
existing tumor vessels. The second group is the tumor vessels toxins which damage existing 
tumor vasculature and. the third group to which END belongs is called the dual action agents. 
whichcombinethesetwoeff«ts 
[n cancer treatment. END is administered as a combinl-d therapy 10 tumor cells. [t acts 
as an adju,·ant and enhances the delay in tumor grow1h. END possesses several properties 
related to tumor necvasculari7.J1tion that makes it different from the other anti-angiogeneic 
factors. First. ;t is a potent inhibitor of Ee proliferation. migration, tube fonnation, and tumor 
growth. Second. it dim:tly induces apopt05is. Finally and the m05t important, it does IIOt 
develop drug resistance which prevents Ee from responding to various proangiogenic 
stimuli.'l.2<.2! 
Since its discovery, END hasbcen reported to ltave many applications in the treatrncnt 
of a number of immunological, viral and neoplastic diseases. These include endometriotic 
lesions.1< a number of different ectopic tumors.1"2'1 coronary artcry discases,.IO 
atherosclerosis.)' rheumatoid arthritis,)l proliferative diabetic retinopathy,)) obesity,'" Down 
Syndrome.H ectopic tumors.J.I> giiosarooma.Jl,ll meUlstatic breast cancer. )9 and different types 
of carcinomas."""'l A sustained and high dose of END was always needed on Ihe target site in 
cases where reaching the lumor site by the sySlemic route is impossible, as in the case of brain 
tumors.JI For Ihe [realment of the diseases mentioned above, END has atlracled eXlensive 
attention and. in the last IWO decades. scienlists have been exploring ils clinical uses and 
theTIlpeuticpotential. Now. angiogenesis inhibitors are being studied in over 100 laboratories 
and 40 biotechnology companies. A detailed list nf angiogenic agents currently under sludy 
may be found in many other reviews.o ... J 
The first human clinical trial s using END began in 1999. This lrial was a phase llrial 
that was designed [0 study the safety of the drug rather than its effectiveness. This type of trial 
typically uses small numbers of patients; in this case, the patients were in adv anced stages of 
metastatic pancreatic and colorcc[al and olher solid tumors. "'""" Even though. END has been 
shown to be remarkably safe and non-toxic compared to chemotherapy, and many patients 
have shown an arrest in tumor gro\\1h. the actual determination of effectiveness took place 
during follow-up trials." Phase II trial s. tltatdirectly lead to Food and Drug Administralion 
(FDA) approval for marketing of the drugs. began in 2002 and ended in 2006 for 
neuroendocrine tumor patienls. The results were disappointing for Folkman's team and many 
OIherresc:archers. and showed no significant tumor regression in these patients. 11ledrug was 
not advanced to phase III studies be<:ause phase Il studies showed no tumor response . 
Folkman and Luo Yongzllang made a few amino acid alterations that made END more 
potent and longer lasting in the blood. This new version of END. Endostar. has returned END 
back to the anention ofresearchers:9 and the promising resuhs ofa phase m study for 
Endostar have been published in a peer.reviewedjoumaL$(I 
Although END has been extensively investigated fora broad range of indications, it 
possesses properties that have limited its clinkal use. Systemic delivery. which is the major 
route used to administer END. has inherent disadvantages. lbese disadvantages inelude the 
necessity of repeated injcctionsduc to the short half-lifeofEND,the fact that treatment nceds 
to be continuous to sustain tumor dormarn;y. the risk of toxicity and the high expense. 
Additionally, dosages used in preclinical studies arc not feasible for prolonged patient 
ihcrapy.!I.!J These limitations have inspired thc investigation of novel modes to deliver this 
angiogenesisinhibitortoenhanceeithertargetingordeliveryinordcrto achieve higher 
therapeutic outcomes while minimizing its shortcoming. In the following s«tions, focus will 
be placed on the difTerent strategies to optimize the angiogenic thempyofEN Dbydescribing 
its physiochemical. pharmacokinetic (PK). and physiological aspe<:ts. Furthermore, emphasis 
will be placed on the best routes and delivery systems used in the local delivery of END. 
2.J MECIIAI\' ISMS Of' ACTION Of' ENOOST A TI N 
As with other FDA-approved angiogenesis inhibitors such as Avastin, researchers still 
do not know the exact biological mechanism of END, Many theories were introduced to 
describe the anti-angiogenic and antitumor activities of either angiogenesis inhibitors in 
general or END in par'licular. These hypotheses include the prevention of tumor spread and 
metastasis through the same mechanism that is invol>'ed in chemotherapy and radiotherapY',\j 
and/or itexer'lS its action !lSgro>1Ith control regulations of the cancer cell sS6 and/or it is acting 
on the immune systcm, <9J7 Until now, most of the issues relating to how END exer'lS its effect 
are unclear. Researeh to determine the exact molecular me<:hanisms for END are still ongoing, 
Many studies suppor'l the idea that tumor cell gro\\lh is controlled by a dynamic balance 
between angiogenic factors [such as vlISCular endothelial gro\\1h factor (VEOF) and basic 
fibroblast growth factor (bFOF) and ongioslatic factors (such as angiostatin or END)] ,'!-'" 
Imbalance between angiogenic promotcrs and inhibitors produces the intense angiogenesis 
which is characteristic of many pathological processes, including diabetic rctinopathy,r.o 
rheumatoid arthritis,61 endometriosisOl and malignant tumors,6.J,6oI Factors influencing 
ongiogenesis are deri1led both from tumor cells and infiltlllt ing cells. such as macrophages and 
fibroblasts. '" The cbange in the balance octwcen angiogenic and angiostmic factors. the 
angiogenic switch, has increasingly become recognized in Ihe field of tumor biology as a 
critical step in IUmorpropagation and progression,66.67 
Migration of tumor and endothelial cells through lhe tissue extracellular malrix is 
facilitated by a group of enzymes known as matrix metallopr01cinases (MMPs). These 
enzymes. which are secreted by the same cells that produce angiogenic factors. are responsible 
for the breakdown of the tissue matrix surroWlding the growing vessels and tumor.'" Inhibition 
of the catalytic activity of MMP catalyzing the proteolysis of extracellular matrix and 
mediating tumor cell invasion into adjacent tissues and endothelial cell migration during 
fonnation of new capillaries is one of lhe mechanisms underlying anti-angiogenic and 
antitumor effects of END.so Some of lhe classical cellular palhways of END are shown in 
Figure 2.1. 
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Figure 2.1 A proposed mechanism of direct and indirect action of angiogenesis inhibitors On 
the endothelial cells. (Diagrams drawn by Hany Ellabondy) VEGF: vascular endothelial 
growth factor. bFGF: basic fibroblast growth factor, and MMPs: matrix metalloproteinases 
In another attempt to detennine the mechanism of action of END. it was revealed that 
the study of the crystal structure of human and murine END showed that END hall a zinc 
binding site and a potent heparin binding site. Tltis zinc binding of END .... 'lIS reponed to be 
essential for its anti-angiogenic activity and molemlar stability.69 In addition. structure-
function studies have implicated heparinlheparan-sulfate binding as being impoMant for the 
activity of END, leading to speculation that END may bind the endothelial cell surface via 
Iteparinllteparan-sulfated protcoglycans. 70 Whether ENL> exerts it effect following cell surface 
receptor binding or, as was r~'Cently reJXlncd. by internalization. remains to be elucidated. 1lIe 
END treatment of endothelial cells has been co""dated to a S to GI block in the cell cycle and 
to specific tyrosine phosphorylation activity suggesting that downstream efT«:ts of END may 
be mediated by specific tyrosine phosphol)'lation events. 70 Another marmer by which END 
elicits its antitumor action is through Ihe indirecl stimulation of the immune system causing a 
sequence of immunological reactions and stimulation of some of the immune system 
comJXlnents. Both humoral and cellular efTects are produced and Ihese may depend on the dose 
of END administrated and its timing in relation 10 the immune process.1' 
END also exerts its indirect cYlotoxic and direct cytostatic action via inhibition of the 
blood supply to tumor tissue. Therefore. the prolonged administration of an anti-angiogenic 
therapy may be necessary to obtain 10ng_lerm suppression of tumor gro .... 1h. Consequently, the 
local dclivCT)'ofapotent anlliollenic inhibitor would be a valuabletreatmen t strntegy for solid 
tumors such as glioblastoma. leading to an accumulation of the anti-angiogenic proteins at the 
tumorsiteinthebrain. ll 
More basic scientific research still nCOOStO be donc tocliaractcrize and trace the 
pathway of the END to ascertain its mechanism of action. Tncre are many other proposed 
mcchanisms.J)·'l but the understanding of how END works is still unclear 
2.4 STRUC1'URE & PltYSIOCIIEJI1ICAL I'ROI'ERTI.;S OF .;N IlOSTATIN 
END is 11 20 kDA C-terminal protrotically cleaved fragment of collagen XVlll. 11 is 
reported to be composed of 184 amino !Kids and is naturally present in many adult and 
embryonic human tissues,16 As a proteolytically cleaved f.-dgment of collagen XVllI . END 
shares the identical amino acid sequences lind secondary structure as the corresponding 
fragment of collagen XVJII 
The structure of END is different fr<)m other angiogenesis inhibitors. Its structure is 
uniqucasitssecondarystructure ismainlyirregularloopsof~-shectsandcontainsonly a small 
fraction of (I-hcliees with two pairs of disulfide bonds in II nesled pauem.'o Mismatch of 
disulfide bond may result in protein aggregation. and multimcr fonnation . howc\'cr the anli-
angiogenesis IICtivity does nOI change. as the multimerexerts its higherlleti vitybyprovidingll 
more suitable molecular structure for molecular interaction with heparin sulfate 
proteoglye1ll\S.71 
TIle ultra-structure scanning of recombinant murine and human END has been carried 
OUI. 7I,.,. and il predicts 11 compact globular protein that probably exists as an extracellulllT 
module even prior to cleavage from collagen XVIII. FurthCTmore. its structure reveals a large 
basic scquence made up ofaclusterofarginine rcsiducs and predicts for Arg 1931Arg 194 and 
Arg 2S9/Arg 260 to be the pulative heparin binding site, Therc arc two interesting and unique 
characters of END. The firs' one is that small fragments of END. with or without cystcine, 
have reman..able anti_angiogenesisactivity. to-IJ lJnlikecylokines, END has no single 10000us for 
its bioactivity and it functions in a diffcrcnt manner. The second one has a great advanlage, ilS 
lackoftoxicit~'andthcfactthat.unlikeothcrcommonlyuscdchemothcrapeuticagents, itdoos 
not 1eadto the developmenl of acquired drug rcsislaOCe." 
END was originally obtaincd by purifying and isolating the naturnllyoccurring protein 
from the supema\ant of cultured murine hemangioendothelioma cell line or from hcmofiltrate 
of patients with chronic renal fai lure,'"' Currently. recombinant END (rEND) is produced via 
recombinant protein technology from different sources including human embryonic celis," 
ooculoviru../ J Escherichia coli, Pichia pmlOris7) and Hunsenula Polymorpha expression 
systcms.76 There is a high degree of amino acid identity and homology reaching up to 99"/0 
between human and murine rEND,S6 
Rewmbinant END produced by an eukaryotie system (yeast, Pichia pmlOris)7J was 
found tobc soluble and soowed both in l"ilroand in ,·j,·o anti-angiogenic acti vitics in various 
tumor animal models. However, the low yield and high cost limited the use of this technique of 
expression for large-scale production. On the other hand, although the use of prokaryotic 
systems (bacteria. Escherichia coli>" demonst,...~ted angiostalic activity and WlIS more 
<xonomical than the eukaryotic system. the END produced by this method WllS insoluble. 11 
was found that bacterial rEND fonns insoluble amyloid fibers which aggregate lIS the j).-sheelS 
of the polypeptide backbones and are stacked via intcnnolecular rather than intramolecular 
h~drogen bonds. thus forming a cross-~·shcet and therefore rendering it insoluble.a 1lle 
soluble and aggregated (insoluble) forms of rEND have similar ph~siochemical properties. 
molecular weight. heparin binding abilit~. and anti·angiogenesis aclivit~"l."'.90 and 
demonstrated no cytotoxicit~ to primar~ human umbilical vein endothelial cells Or 10 human 
dermal microva5CularendOlhclial cells.91 
Recombinant END has been reponed to have the same biological activit~ as naturall~ 
occuring END'; but. as with man~ other recombinant proteins. it possesses some differences in 
its gl~cos~lalion.92 11 is r<.-.:ogni7'cd lhal. in contlllSt to the nalUrnll~ occurring END. rEND 
partiall~ or oomplctel~ lacks the carboh~drntc moieties atta<;hed to its structure which 
decreases the half·life of the rEND in the blood stream.9J-"l 1lle carboh~drnte chains in END 
are of mucin t~pe with galactose N·acet~lglactosamine core unit of O.gl~cans,W. and usuall~. 
this disaccharide is substituted b~ one or Iwo sialic acid moites." The sugar moiel~ in END is 
assumed to increase its solubilit~. it protects the END from undesimble digestion b~ enzymes 
and regulates Ihe intcmctions of END with cd! receptors." II was found that different 
gl)'cos~lation levels regulate intracellular signaling cascades relevant to tumorigenesis.91-91 
Funhermore,thelevelofgl~cosylationdiffersbetwcen the in VilrQ and the in vil'QwhiCh can 
be attributed 10 the factlhat thegro",h conditions of cells in a living organism promote the 
g!yoos~lationinawa~lhathasnotbeenreproducedin'·ilro.92 
END is basic. with an isoelectric point at about pH 8.93."'" It is reported to be one of thc 
ocid·resistanl polypeptides that toleratcs acidic condilions. 11 was found lhal END remains 
stable and keeps its activity and nati\'c structure at a pH as low as 3.5. Such acid resistance 
mighl be anribuled 10 ils lighll~ pack.ed SlrtlClure andlor due 10 its 10\'Icr accessibility 10 protons 
andIor due to its stable confonnation. Recently, trifluorocthanol has proven to stabilize the 
helical structure of native END by strengthening the hydrogen bonds. Therefore it makes END 
more acidic resistant in the lower pH region. However. it is found that END partiaUy or 
compk1cly degl""ddes at pH values less that 2.0. ,G On the other hand, END, like other 
polypeptides is very sensitive to heat. The triple helix ofdeaved collagenmo leculesundergo<:$ 
thennal melting at 37°C and thennal denaturation and unfolding of intact collagen molecules at 
temperatures greater than 42°C.' oo 
2.S TUE PUARMACOKINETICS O F ENI)OST A TI N 
The maximwn level of END concentration in the bloodstream is dependant on its 
physiochemical properties which include size, molecular ""'eight. degree ofglycosylation. '" 
dosage fonn. and its route of administration."·w, The intravenous (iv) route has been used for 
END delivery,'O,.,02 however. other routes ofadministmtion have been used in various clinical 
studies which include intratumoral (im),I OJ, loo intraancrial (ia).' O» intraperitoneal (ip).''''' 
intracerebral(ic),'o'aoosubcutanoously(sc).'Ol 
Recombinant human Endostatin (rhEND) has a shon elimination half_life time after iv 
administration in rats. '09 END given by the sc route to Rhesus monkeys has a longer half-
life. 11 0 The sc and im routes result in a more e~tcnded half·life because these two routes fonn a 
depot after injection that allows a slower release of END. Simultanoously, other researchers 
attempted to prolong the half-life of END using an antibod~ moiety and achieved a four fold 
,ncrease.'" 
Pegylation technology is a pa!1icularly attractive approach to increasing the utility and 
efficacy of injectable drugS.IIl·lIl The tenn pegylation refers to the conjugating of protein 
drugs with the polymer poly-cthylcnc glycol (PEG). Because altering the drug molecule can 
improve both the phannacokinetic and the pltannacodynamic pmpe!1ies of the drug, pegylated 
drugs generally have longer plasma half-lives and durations of bioactivity than their 
nonpegylated o~. Pegylation pmvides the drug with many benefits such as greater biologic 
activity. longer circulating half-life. less enzymatic degradation. less immunogenicity and 
antigenicity, less toxicity, greater solubility, less-frequent administration, better patient 
adherence and improvcd quality oflifc. lI l. ll ' 
Whether given by IV. sc or im. END requires a relatively frequent and repeated regimen 
of administllltion. For example. the dosing schedule for the treatment of adcnocarciooma is iv 
bolus 300 mi§m1fday.101 This dosing schedule requires a health care professional. adding a 
health care burden, and is hurtful,painful and inconvenient forthepaticn!. Thcrefore.thereisa 
need for a delivery system that docs not require th~ dai ly involvement of a health care 
profcssionalandiorioconvenientlifcstyleforpatiem 
2.6 LOCAL VERSUS SYSTEMIC DELIVERY O F ENDOSTATIN 
Local administration might be an excellent solution to overcome the many challenges 
forthc dclivery of END. 
There are several papers in the literature that emphasize the usc of END for the 
treatment of different metastatic tumo",. and other clinical conditions. However, few have 
reported on the mo~t effective and lea~t toxic routes of delivery. The major routc of END 
delivery to the human body is systemic, (iv. im, sc. and ia),oL.lm.w',l Ol Systemic routeS have 
tremendousdisadvantagcs, such as thc uneycnand unexpected distribution of END fragments 
throughout the body tissues and fluids. sometimes at a distance away from the tumor bed,lll In 
addition, the concemration of END in the blood streanl does not necessarily reflect the 
therapeutic outcome.'OI, .. O Funhennore, the di lution effect. hepatic melabolism. and 
glomerular liltration will reducc the END concentration in a very short time and consequently 
will reduce the bioavailability of END. Fortunately, the high dose of END to which different 
organs and tissues are exposed have minimal toxic or side-effects on the function of the 
organS.JI.11.l16 
END has a shon half-life in the bloodstream; therefore, this shon time would 
minimize the exposure of many tumor sites that need high doses. Additionally. the high 
doses used in preclinical ,tudies are not likely to be feasible for prolonged patient 
therapy. I" The cost of END production and the painful regimen of delivery is not suilable 
for cancer patients. rhe fact that treatment needs to be continuous to suslain tumor 
donnancy necessitates repemed injections. 
END has required doses as high as 20 mglkglday to demonstrate antitumor responses in 
mice l ! If similar doses are required in humans, systemic administration of END to cancer 
patients is not fcasiblc. ll Human END is rapidly cleared from the blood and therefore. to 
achieve significant tumor regression, a high amount of END would be required. These 
challenges have inspired a se:m::h for novel delivery systems to enhance cither targctingor 
deli,·eryofEND, .... 
Local administration of higher doses of END. up to 20 mg per kg. daily via 
intmcerebrul microinfusion caused potent inhibitory effect on Lewis and ovary 
carcinomas. hemangioma (EOMA). fibrosarcoma "1141. melanoma BI6F10. and in some 
cases. END caused total regression oftumOrll.'" The antitumor potential of END with the 
lock of marked nonspel:ific toxicity and tumor resistance allows it 10 be considered as a 
promising antitumor chemotherapeutic agent. However. the development of a stable 
effect requires the use of high daily doses (from 10 [0 100 mg per kg) because of 
cbaracteristic dis[ribulion and excretion of [he administCTed protcin. l • Phase I siudies with 
rhEND given as daily iv bolus injcctiOI1!l showed no drug-related toxicity. HowevCT. the 
pharniacokinetie analyses revealed that, at the highesidose thai could be pra<;ti cally 
administered, the drug exposure was lower than that yielding maximum tumor growth 
inhibition in preclinical studies:? 
Many research paperll have reported on the delivery of angiogenesis inhibitors 
using different routes of administrations and compared theefficicncy and safety issues. 
Daily systemic administration of2.5 mglkg END for more than 16 days resulted in a 530/. 
inhibition in tumor groMh in a Lewis lung carcinoma modeL' l In a renal cell carcinoma 
model, rhEND injected daily sc (10 Ilglkglday) around the tumor for four days led to a 
61% inhibition of tumor gro"1h after 20 days.7I Many researcherll have demonstrated Ihal 
local or systemic administration of non-viral END plasmid significantly inhibitcd the 
groy,1h of sevcral twnor types. including lung, brcast, kidncy. and sarCOma twnO,,!,1I9 
Howcver. 3 sustained local high concentmtion from parale~ional injections ""suited in a 
dose-dependent improvement of the antitumor effect and a cure rate that might be greater 
than that from a systemic administmtion.'·l06.IIl Therefore, a continuous and local 
delivery system would provide a significant improvcment over the other routes of 
administration 
Continuous local delivery of END may offer an effective therapeutic approach to the 
treatmcnt of 3 varicty of tumor typcS,72 It provides a high drug concentration around the tumor 
tissues and atihe same time reduces the exposure of the surroundings to tbis angiogenesis 
inhibitor. Recently. several stratcgies including an osmotic pump. cell encapsulation. polymer 
implants and recombinant tedlDology, have becn examined to demonstratc the efficacy oflucal 
deliwryonthetherupcuticoutcume, 
In studies cxamining the efficacy of continuous deli~'ery of angiogenesis inhibitors, 
Giusanni <:\ aI., re<:ently showed that continuous local ic delivery via an osmotic mini-pwnp 
connected to an intracranial catheter resulted in higher antitumor efficacy against established 
glioma xenografts compared to continuous systemic administration or daily injections.'10 In a 
similar study. Kisker et al.. have reponed that continuous delivery of END could be achieved 
using osmotic pumps.'06 ln another study. Alzct mini osmotic pumps implanted ip and used to 
administer END continually to 5C Lewis lung careinoma led to 81 % inhibition in tumor size 
compared y,ith a single bolus administration of 100 mglkglday for 23 days. which led to 90% 
tumor inhibition. However. tliese mini-pumps had to be refilled every 7 days to ochieve this 
levelofinhibition.'01 
Cdl encapsulation technology for END presents several advantages including the 
sa:retion of de novo produced END.' I' and it oven:omes tile major problems that confront the 
systemic delivery of END for use in the treatment of brain tumors. III Some studies 
demonstrated that a single administration of microencapsulated enginet:red cells that 
continuously sa:rete END significantly inhibited hwnan glioblastoma xenografts. Animals 
treated with encapsulated END cells e.lhibit a 72% inhibition in tumor growth 21 days post 
microcapsule injcction.n The encapsulation delivery system allowed local and continuous 
rdease of biologically active human END for the treatment of glioma. This delivery technique 
may be useful for the treatment of brain tumors. wherein the blood- brain barrier can impede 
systemic treatment of anti-angiogenic agcnts. Increasing the amount of encapsulated cells may 
permit a higher concentration of human END to be obtained, whkh may lead to higher tumor 
inhibition.'2 
The abovc strategy aimed 10 enhance local delivery of angiogenic inhibit ors by the local 
implantation of encapsulated producer cells engineered to express END. In two studies 
examining thc cfficacy of this approach. a reduction in twnor grol'.1h of over 70"-" inonhotopic 
glioma twoor models was foundo.n.lD In addition. Dr. Tracy-Ann Read and her colleagues at 
the University of Bergen have described a method that deli"en cells capable of producing 
END dircctly to the site of the tumor, but in the fonn of gel covered beads that are unde tected 
by the immune system. The team injected til<: beads into the brains of !"DIS that WCrt already 
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induced to develop a gJioblaswma. Dr. Read'~ tearn observed that 70010 of the beads remained 
viable, compared with the non-protected control cells, and that END was sl'crded from the 
beads for at least four months. The treated rats survived 84% longer than untreated controls. 111 
The utilization of polymers as a drug delivery vehicle has been used in the therapeutic 
scning. and provides a new method for local delivery of anti-angiogenic agents within the 
polymer directly to malignant brain tumors. II' The biodegradable polyanhydride-poly-(bis-
[carboxyphenoxy-prupane]--sebacic acid) polymer (pCPP:SA), unde'l!lOCS slow but complete 
hydrolytic degradation in the presence of water alKl releases biologically active END in 
continuous and sustained fashion either in vivo Or in vitro. Biocompatibility studies of 
pCPP:SA have demonstrated that the original compound and its degradation products an.' 
noneywtoxic. nonmutagenic. and nonteratogenic. 'l! In addition. the clinical testing 
demonstrated its safety and efficacy,1l6.121 therefore, this drug delivery polymer has bcrome 
"idely used clinically for local drug delivery in patients with malignant1Umors. Local drug 
delivery using polymer has rnany advantages over other systemic delivery routes of 
administration 
Another therapeutic approach involves surgical removal of the tumor followed by 
implantation of a biodegradable controlled·release polymeric device loaded with an 
antineoplastic agent such as angiostatic steroids, tctra\":yclinc derivatives, and arniloride in the 
resulting cavity. This method would provide a high local drug concentration. effectively 
destroying surviving malignant cells and would also pre\'ent the systemic side effects of 
chemotherapy normally associated with its iv administration. It is currently being studied in the 
laoorntoryforlocaldc1iveryofavarictyofanti-angiogenicagents. I2I Forexample.implantablc 
controlled-rein"", polymers for local drog administrntion directly into the tumor parenchyma 
have bccn deve!ope<! to achieve therapeutic concentrationsofthesedrugs ..... ithin the brnin 
while minimizing syst~mic toxicity. Controlled·release polymers used as a drug delivery 
stl'atcgy provide a clinically practicable method ofachievingsustai ned anti-angiogenic therapy 
..... hich can be readily used in combination with other treatment modalities such as 
cytorcductive surgery. radiation. and cytotoxicchcmotherapy.'11 
lhe systemic administration strategy has many disadvantages su<:h as the shon 
halflife time. lowerdrog concentration aroundthetumorbcd and side effects on the other 
organs, not to mention the pain and patient inconvenience. On the other hand. local 
delivery would provide an improvement o,'cr systemic administration. Various methods 
for local delivery including osmotic pump. cell encapsulation and polymeric devices have 
bcenexamined. Thc polymeric drog delivery technology was shown to be feasible as a 
tool to localizc thc drug. 
2,7 SU~,A l l\'E I) VH GUS PliLSAT1U: RELEASE OF ENIlOSTAT1N 
In light of the aoovc discussion. it is necessary to kno ..... whether a pulS3tile 0 I' sustained 
release of END is required 10 achieve the maximum therapeutic outcome 
In the pulsatile mode of administration. the cells are exposed to pulses of the delivered 
END followed by a time- and dosc:-dependent decrease in the effecl. This method of END 
delivery ..... asthe focus of one of the studies conducled by Ding et al.ll'>Thcymoni toredille 
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elIect of massive pulsatile or multiple and prolonged adminisuation of END by localized im 
injection of plasmid on murine manunary carcinomas. Although they reponed that this strategy 
of administration was successful and had a potentially acti\'c anti-angiogenic effect. it was 
clear that this method of frequent administration would be an inconvenient and irritating 
methoci of drug deljvcryto the canccrpatient. 
Kuroiwa ct aI .. used recombinant tcchnology to deliver the mEND gene. In these 
cxperiments, they demonstrated that rhEND was rapidly cleared from the mouse circulation 
after an inteTmillent sc dosing regimen of human neuroblastoma xenograft model. which may 
explain why oontinuous local delivery was more efficient and improved the END activity. In 
addition. the constant presence of ThEND around the tumor bed would minimite the acute 
pathological effect in which the secretion of END would remain active as long as the gene is 
expressed. '10 They also ooncluded that continoous administration of rhEND resulted in more 
significant1Umor regression than intenniltent administration of the agent in the same model. 
This indicated that rhEND, if administered in continuous fashion. could become an effective 
agent for treating patients with neuroblastoma 
Inanothcrstudy. it was documented that high local continuous angiogenesis inhibition 
therapy was more effective in the treatment of gliosarcoma. The researchers genetically 
engineered gliosarcoma cells so that they would stably secrete END. END· producing 
gliosarcoma cells were implanted intmccrebrnlly in rats. lbc antitumor efficacy of END was 
evaluated on the basis of survival data and tumor volume compariOOJl$. They confiTmed that 
the continuous release of END by the END-producing cclls significantly inhibited tumor 
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gro"th, Notably, 40010 of the animal ~ in the treatment group experienced long-term survival. 
without histologically verifiable tumors. seven months aftcr cell implantation. Furthermore. 
turnor bl<.>O<l plasma \'olurnes were reduced by 71%. microvesscl density counts by 84%. and 
vllSCulararea frnctions by 75%.1J1 
Reaching and maintaining therapeutically efficacious levels of END could be achieved 
either by continuous or repeated injections. (i.e. systemic administration) or by a mechanism 
whereby the protein is eontinuousl~ secreted by an implanted device (i.e. local administration). 
By using a local system. lower doses of the effective anti-angiogenic protein may achieve 
significantturnor suppression. 71 Continuous dosing with anti-angiogenic agents such as END 
would replocc interminent dosing and would result in a more acceptable endpoint of the mode 
of administration. 
Based on the rliscussionjust presented. it can be eoncluded that the most effieient and 
least toxic delivery system for END is a localized and sustained release dosage form. Such a 
delivery slrntegy would minimite the exposure ofthc other cell s and organs to the stimulatory 
andiorangiogenctic inhibitory effects of this potentangiostatic agent. 
An application of the development of a local delivery system for END would be in 
combination therapy with currently used treaunenlS. The combined application of angiogcnetic 
inhibitors could be a promising stratcgy for canccrthcrapy. 
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Preliminary in >'ilro data described an increased effect when two angiogenic inhibitors 
"'-cre applied in combination. Sevcral studies havc reported on theadvantagcs ofcombining 
anti-angiogenic agents with immunotherupy. chemotherapy or radiOlhernpy. The reason for 
thc$ecombinationsistheassumptionthatthevariousmechanismsofaction and various targets 
could lead to additive antitumornl effects. IJl,1ll Many other studics sug gested that the addition 
of anti-angiogenic agents to conventional thernpeutic wategies such aschemotherapy.' l4-1J7 
rndiation. IlI·I:MI or other tumor-targeting agents,' 40 will increase the clinical efficacy of these 
diffcrentapproaches. '·' · .. J In an attempt to enhance the response to thernpy. Mauceri et aI., 
combined radiothernpy with a systemica!ly-administered angiogenic inhibitor via ip injection 
twice daily at a total dose of 25 mglkglday. They reported significantly enhanced antitumor 
efficacy coinciding with reduced ncovascularization in several tumor models including 
glioblastomaxenograftcdinmice. 1ll 
The anti-angiogenic effects of metronomic ally scheduled chemotherapy (a frequent 
low-<lose schedule regimen) may be enhanced by combining chemotherapeutics with anti-
angiogenic inhibitors. Metronomic chemotherapy in combination with the anti-angiogenic 
compound caused the eradication of drug-resisUln\ li:wis lung carcinoma xenografts. This 
result was not obtained with conventionally scheduled chcmotherapy (long i11lerval betwecn 
cyc1es)alone." ·'J< 
Enhanced anti-angiogenic effectivencss has been reported for the combination of END 
with angiostatin,' ..... , and for END with chernothempeutic agents.' " Furthermore. the 
combined therapy with receptor tyrosine kinase and END enhanced the anti-angiogenic effects 
in human ECs in vi/ro and enhanced delay of tumor gro"1h of human ~enografts of prostate 
ooenocardnoma. lung cancer. and glioblastoma. llIe data confinn that combined treatment 
with direct and indirect inhibitors of angiogenesis may result in synergistic ami·angiogenic 
activity, imp ...... vi ng the overall antitumor efficacy of these agents. SoI. !'1 END not only 
significantly suppresses tumorgrowlh but also enhances the amitumorefficacy of radiation 
thell'lpy in human carcinoma ~enog.raft.I"'" Ultimately, anti·angiogenic therapy may provide an 
lIdditional strategy for combination with standard thelllpies.I50.111 
From the abo"e discussions. it can be concluded that a sustained release and a loxali:red 
delivery system for END treatment. either alone or in combination with other therapeutic 
agents, would p ...... vide the besttherapeulic result 
2.9 ADVANTAGES AND DISADVANTAGES OF VARIOUS DELIVERY SYSTEMS 
Several strategies have been im'estigatcd to fonnulate and deliver angiogenesis 
inhibitors while at the same time trying to achieve two major objn:tives. The first is to deliver 
and target those inhibitors, such as END, slJC(:ifically and safely to their site of action to 
maximize thei r therapeutic efficacy while minimizing their tox icity. The other is to QI'ercome 
stability iss<>esduring the prepallltionofdosage fonns containing these ang iangiogenic agen ts 
and to help in maintaining this stability during storage of the dosage fonn and after 
administrati<:>n to the patient. 
Early srudies ofENO "-ere focused on achieving a localized. continuous and controll ed 
release to help in improving the thelllpeuticoutcome. These studi~"SincludedextensionofilS 
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half·life in plasma and in reducing the amount to which the areas surrounding the tumor .... 'Cre 
exposed.'O,1I2 A "ariety of strategies of achieving localized delivery of END have been 
explored and investigated including the use of liposomes, biodegradable polymers, 
eneap5ulation.and gene thcrapy. wilh varying degrees of suCcess. 
In gene therapy tcchnologyforanti-angiogenesis. a wctor is used to insen a gene for 
the expression of angiogenesis polypeptide inhibitors inlo a host cell to over express this gene. 
This process can be conducted using virnl vectors including retroviruses, lentiviruses. 
adeooviruses.and adcno-associated viruses or nonviral vectors including cationic liposomcs. 
microencapsulation. polymers. and naked DNA. and can be accomplished with in vivo or in 
vitro senings. The advantages of gene therapy ovcr the direct administrntion of the inhibitors 
include the localized delivery and sustained cxpression of the antiangiogenic molecules. the 
abi!ityto inhibit multiplc angiogenic pathways with the delivery of more than ooe transgene. 
the generation of properly folded inhibitor mok.:ules. and thc potcntial for decreasing the 
COS!.'ll This method has been used in se,'eral studies to obtain a high concenlIation of 
continuous and local END. 
Severn! studies have reported the inhibition of tumor groll'lh and metastasis in mice by 
ndenoviral vector-mediated dcli>'cry of END. however. no strong activity against pre_existing 
tumors was reported via this mcthod.ll.l",m These results contrast sisnificantly with those 
observed using repeated injections of high doses of recombinant END protcin.'I(l As suggested 
by Sauter el al .• this discrepancy can be explaint"d by the insufficient expression levels of END 
by the adenovirus system. but it is more likcly that the innammatory and immune responses 
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induced by adenovirus infection caused the loss of transduced cells and thus resulted in 
transient gene expression. As a result. the reduction in tumor gro,,1h stoppcd OnCe the vector 
was gone and END expression "as 10s1.l'\l Most human tumors arc difficult to establish as in 
vitro cell lines, and extensive ~ubdoning and in vitrQ replication might change the original 
antigenic composition of the original tumor. Moreover. it may take several months to transduce 
a tumotcel!. Such patient-individualized th~rapyis therefore very co~t intensive 
Many researchers have reported On the use of liposomal fO!1llulations of END in gene 
therapy. Liposomal fO!1lluiations can be viewed as a self-assembled polymer. Some of the 
more interesting experiments lIIe described below. The END gene could be efficiently 
transported into the mice with a transferrin·liposome-DNA delivery system utilizing an aerosol 
spray. TrnnsfelTin-liposome-mediated END gene therapy strongly inhibited angiogenesis and 
the growth of mouse xenograft liver tumors. It also could promote the development of 
apoptosisoftumorcellsindirectly.1 1-I In another Sludy, the rcscarchersdesigned an orthotopic 
osteosarcoma model grafted in immUnQ<;ompctent rats. a tumor model that reproduces the 
phenotypic and metastatic characteristics of the osteosarcoma in humans. In this model. they 
evaluated the therapeutic potential of iv administration of END cDNA complexed \0 cationic 
liposomes. The cationic liposomes used in this study possessed a particular affinity for tumor 
vessels compared to nO!1llal vessels . The results showed the ability of iv administered END 
cDNAlcationic liposomes to delay tumor gro"1h. moreover. it effectively prevented the 
occulTence of lung metastases. which is the major reason for poor prognosis and death in 
oSleosarcomapatienls. lll 
Dutour et al.. have demonstl"dted in vilro and in vim that END can be secreted by 
cDNNcationic liposome complexed (cDNNCLP) with plasmid DNA in tnmsfected cells. This 
complex was used for END gene tnmsfer into onhowpically implanted mice breast tumors 
The animals were treated intravenously three times a week. The results demonstrate that 
therapy using END·cDNNCLP is associated with a marked dclay in tumor growth. Moreover. 
it effectively prevented the occurrence of lung metastases. tIl High levels of circulating END, 
resulting in an anti -tumor effect, were achieved when appropriate adcnoviral ,·~'Ctors were 
used. ll6 Systemic (IV or im) delivery of non-viral ve<:tors, as described by Chen et aI., resulted 
in very low in "i<'O coneemralions of END, though sufficient 10 exen a therapeutic effeclY 
Liposomes have the advanlage of easy administration by injection oraeroso I spray. but 
they have the disadvantage of having relatively short drug rcleaseduratio nswhich leads to the 
need for additional multiple injections which are p;linful to the patient. Funhermore, the release 
profiles from liposomcs arc neither sustained nor controllable. Ma el al.. examined the release 
period of human END with liposome and they foond that it is relati,'ely rapid with only a two 
day release timo, therefore long-term END stability in this fOmlulation has yet w be 
demonstrated_Ill Thus. liposomes do not appear to be optimal for sustained delivery. In 
addition, liposomcs arc considered to be a foreign object by Ihe hos1. As a result ,Iiposomesare 
m:ognized by the mononuclear phagocytic system and trapped by the reticuloendothelial 
system in which macrophage-like cells reside. III 
Anotherstudyhasfocu~dontheincorporationandre1caseofEN l) frompoly·L·lysine. 
alginate microcapsules. Rokstad et a1.. examined the potential of microencapsulation of 
genetically engineered cells as a delivery system for th~"Tnpeutic proteins. Parameters that affect 
capsule integrity such as homogenous and inhomogenous gel cores were evaluated, l1Ie 
tnmsfected cells producing END reached a plateau phase in growth after 23 days post· 
encapsulation. however. after 30 days a fraction of the microc.apsule sstanedtodisintegrate.'¥1 
TIle END release was almost constant , However. release dumtions were not long. only 23 days. 
Although alginate·based particles haw demonstrated biodegradable. biocompatible 
properties,IM further improvements are necessary with regard 10capsule integrity as well as 
controlling the cell gro"lh before this technology can be used for therapy. 
Gene therapy has potential. however. there are a number of challenges for using this 
method as a pharmaceutical drug delivery system, Viral vectors are commonly used as carriers 
for gene transfer due to their high in "irrotnmsfection efficiency. but the saf ety issues and thc 
toxicityofthcsc viral vectors will likely preclude their usc in humans. Inc ontrasl.systemically 
delivered non·viml liposome:DNA complexes have been shown 10 have low toxicity.'61,'02 
Neverthcless. asthc goal of anti· angiogenic therapy of cancer is the long·tennsUPJlfl:ssionof 
IlCOvllSCulari :wtion and twnor growth. there is another important challenge for current gene 
transfer veclOrs. which ei ther provide only temporary expression (c,g .. non viral ve<.:tors)or 
elicit host responscs that conspire to eliminatc the genetically modified cell s(c.g .. !ldenovirus 
veclOrs), Another problem associated with anti·angiogenesis gene thempy is the low gene 
transduction efficiencies thaI occur with common cancer gene therapy." 
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Implantable biodegradable polymeric devices provide a unique practical means of 
localizing angiogenesis inhibitors at the tumor site. The strategy of using a polymeric 
controlled delivery device reduces the amount of protein needed, relative to systemic 
administration, to achieve similar angiogenesis inhibition. END fragments were loaded into 
pCPP:SA biodegradable polymers. The pharmacokinetics of END/polymer formulations were 
evall.lllted in ";lfO in rats having gliOSllJcoma. Biologically active END was delivered from the 
polymer in a controlled-released and sustained fashion for 19 days witoout any sign of local Or 
systemic toxicity. lI The advantages of biodegradable polymers as a delivery vehicle are that 
they degraded into small biocompatible monomers and could be excreted via normal excretion 
process in the body and so surgical rcmoval would not be required 
These delivery systems comprise a biodegradable monolithic polymer, throughout 
which the drug is distributed as separatc solid panicles. Ely immersing the device into the 
medium, the protein drug was released in three stages. an initial burst follow edbyadiffusion-
controlled release. and finally an erosion-controlled relea.se.16J.IM Poly(lactidc-co-glycolide) 
PLG microsphcres are among the most extensively studied polymers for the delivery of 
proteins and cytokines. l6j They havctheadvantagesofoot only providing ac ontinuousrelease. 
but of being easily delivcred to the targel site. ha"ing a reasonable shcl f-life,ofTering a long-
term release duration, and consisting of biocompaliblc materials. Despite these benefits, the 
major problem w;th using a polymeric dcli,'cry system in general is keep ingthcpro!einstablc 
and active during loading into the devices. storage and during release into the surrounding 
environment. Polypeptide drugs are susceptible to aggregation, denaturation, dcamidation, 
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cleavage. oxidation. thiol disulfidc exchange. and J} climination in aqucous solutions. There are 
many factors that cause these changes including ionic strength, light, pH, temperature and 
mechanical stress and presence of oxidizers and radicals. Protein aggregation may result in 
conformational structural changes in the protein molecule and loss of activity . ' '''' 
Polymeric microsphcres are capable of dclivering an almost constant amount of an 
cncapsulated polypeptide. Microspheres synthesiz.ed from PLG with different co-polymer ratio 
could be formulated toreleasetheircontcntfordiffcTCl1tpcriodsoftimcrangin g from weeks to 
months. This feature enables researchers to design a delivery system to release the whole drug 
content before microsphcre dcgradation has taken place. It has bc<:n reported that anti-
angiogenic factoN,uch a. hemopexin and platelet factor 4 fragmen15. h ave been incorporated 
into PLO microspheres. The rcsearchers examined the effects of mierospheres prepared by 
water in oil in water emulsion (w!o!w) On the release and bioactivity of these angiogenesis 
inhibitors after a single local se injection in nude mice having gliom a tumors. The stability and 
biological activity of these angiogenesis inhibitors were maintained during the fabrication 
procedure. The results were extremely promising as there was a 88%_95% redU(:tion in glioma 
tumor volume 30 days posHreatrnem. , ,1 
One specific problem of using the PLO microsphere is the centml accumulation of 
acidic degraded monomers within the sphere and the denaturation of the incorporated 
polypeptide drug. When biodegradable polymers .uch as PLO degrade in a medium. they 
produceby-product~calTyingcarboxylic acid end groups that lower the local pi! at the surface 
of the polymer and in the pores and channclsofthe device."'.1 61 Fu ct al.. ha sc\'aluatedthcpH 
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at the center of PLG microspheres to be as low as 1.5. This major decline in the pH of the 
micro.pheres has I".""n linh-d to inactivation and aggregation of other proteins within PLG 
microspheres prior to being released into the surrounding medium."'" Although END is 
dcscribed as an acid resistant protcin at a pH of 1.5 - 2. denaturation and confonnational 
ehanges are unavoidable and a subsequent los,ofaclivilywill takeplaee 
END is a very acid-re,istant protein and contains some of its native strudure even at pH 
2. Stability measurements of END in urea show that END is still in the nativc structure at pH 
3.5 despitcthc decreased stability.lo This re,istance may be due to itstig htlypackedstrudure. 
its lower accessibility to protons. a result of its stable confonnation 'O or from the contribution 
of the disulfide oonds. l70 The acid-resistance property of END may have biological 
significance in that it cannot bc easilydillested byproteases in an addic environme nt such as in 
a lysosome in the cell or acidic monomer in the release medium. Furthennore, rEND, as well 
as many other recombinant polypeptide drugs. is Illostly liable to dcnatura tionand aggregation 
when presented with a high concentration because when this recombinant protein is fonned via 
genetic engineering, the glycosylation level of the polypeptide mokcule changes 
drastically.97.171 Therefore. many researehers have attempted to stabilize the proteins in 
solution. by the addition of carbohydrates. amino acids. and polyols such as trehalose.m -Il' 
There does not appear to be a report of END incorporation into PLG mkrospheres. and 
subsequent stabi lity of the release. However, instead of using such a device with END, the 
problem of microsphcres degradation could be avoided by using a high osmotic excipient that 
allows and accelerates the complete END release befon: significant polymer degradation 
occurs. lnastudybyGuetal in 2007. it has bcen proven that a constant drug release rate is 
achievable from a polymer in which the drug is distributed as discrete particles in an 
clastomcric monolithic netwon::. As a result of osmotic octivity. ruptures and cracks are fonned 
in the polymcr matrix and the drug was dissolved out into the surrounding medium.'7(i The 
above delivery system scems promising for END delivcry. but the effcct of the delivery 
vehicles and release mechanisms on the stability and activity of this angioge nesisinhibitorare 
still under investigation 
2. 10 CONCLUSIONS 
Long-tcnn and localized delivery with sustained release of END alone or in 
combination with other therapies is a desirable goal for angiogenesis therapy to over(ome 
metastases and tumor oUlgro"th. In addition. the fonnulation strategies investigated to date 
possess a number of desirable properties that make them promising delivery systems, but are 
limited due to their inability in maintaining END stability and activity prior to being released 
from the drug delivery device. 
It would seem that a biodegradable, biocompatible and implantable polymer would 
provide a novel strategy to localize drug delivcry of END 
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Chapter 3. No\-cI I·QI)'(Octancdi"I.Tarlarat~) (POn Biudegradablc Elastomers for 
Drug Delivcry and Uiomcdica l ApJllieations. 
3.1 AIISTRA(. ... 
I'urpf)s~: To synthesize and characterize a series of a novel family of thermal 
crossliked biodegradable pol),(octanediol.tartarutc) (pOn elastomers and to modify the 
mechanical and physical propcrtics by adding a crosslinking agem 
Method: Saturated. aliphatic. low molcmlar weight. amorphoW! thermoset. 
biooompatible and biodegradable pol),cster ela5tomers consisting of L-tartaric and 
1.8-octanediol were prepared and characterized. llJe elastomcrs were produced in two 
steps_ First, the aliphatic saturated !XJ1)'c~ter prepolymcr was synthesized via a 
polyesterfication polymerization reaction. Following purification, the living 
poly(octanediol-tartarme) prcpol}mcrs (POn were funher thermally crosslinked with 
different ratios of the crosslinking agent, 2.2-bis(&-caprolactone-yl)·propane (Bep). to 
prcpareerosslinked clastomersthat could beuscd for implantable drugdeli\'cry an dtissue 
engineering applications. The polyester prcpolymers were charucterized by mCanS of 
proton nuclear magnetic resonance ('H-NMR), Fourier transfomt infrared analysis (FT_ 
IR). differential scaroting calorimetry (DSC). li4uid chromatography with mass 
spectrometry detection (LC-MS). and molecular weight analysis. The final POT 
elastomers were also subjcctcd to swelling studies. sol-gel content analysis. mcchanical 
testing. and long ICrm in ,-ilro acccicratcd degradation studies 
Results: 'H_NMR and Ff-IR analysis confirmed that a pure preparation of the 
POT prcpolymcr was obtained and also confirmed the formation of ester bonds in the 
backbone. DSC showed that the prcpolymer was of semicrystalline nature with a 
corresponding low glass transition temperature (Tg) of -16.2 "C and a sharp melting 
endotherm at 57.2 ~c. Molecular wcight analysi s reported a weight avcrag~ molecular 
weight of 1250 daltons. The final crosslinh-d POT eia",omers had amo",hoUi; structures 
with Tg ranges from -10 to -5 ~C depend ing on the crosslinking density. Sol content 
ranged from 2.2 0/. - 9.8 0/. and depended on the amount of UCP used. Mechanical 
properties including Young-s modulus. % strain. extension ratio all dem'msUated 
dependence on crussl inking density. The elastomers were soft with physical properties 
similar to those of natural elastomers such as e la~tin. Accelerated degradation studies 
demonstrated linear loss of mechanical properties with time and confinned bulk 
hydrolysis as being the predominant mechanism ofpolymcr degradation 
Condusions: Thc novel POT biodcgradable polyester elastomers havc promising 
use in drug delivery and other biomedical applications including tissueengineering 
3.2 INTRO])UCTION 
Thc use ofbiodcgradable polymers in tissue cngitleering. ' ''' getle thelllpy. j·6.and 
drug dclivery systcms1.<J has motivated lhe dcvelopment of novel biodegradable 
elaslOmers. '<),'l Biodegradable polymers with elastomeric features dcmonslmtc elastic and 
flexible properties which rcsemblcthosc of the human soft bodyorgansandt;ssucssuch 
as blood vessels. hcart valvcs. tcndons and cartilagcs. l.Il-Ij beeause of their ability 10 
adjust 10 the mechanical environment.'· n",refore. tney can easily adapt 10 a variet~' of 
mechanical ,limuli when Ihey lin' implanted into a non-static part of the body 
Biodegradable ela~tomers are syntnesi7-Cd as one of two types: thennoplastie or 
thcmtoset. Thennoplastics na~e the advantage of being easily processed by melting, The 
crystalline crosslinked hard regions of tnese materials provide regions having a slower 
and heterogeneous degradation prome. However. the amorphous regions degrade faster 
tnan tnc crystalline regions and produee a material whose physical and mechanical 
properties degrade in a non-linear fashion ," ThemlOsetsare not easily fabric atedbyheat. 
but the rate of degradation is more unifomt. Therefore. they keep their dimensions for a 
longer period of time with lheir physical and mechanical propcrtics ehanging in a linear 
fashion, n.emto<;C\s. therefore aUract the attention of many researcners due to their 
advantageous properties with resJlCCt tocontrollcd drug dclivery applications. 
Polyesters degrade b~' simple hydrolysis in an aqueous environment. such as body 
fluids. bccause of the hydroxyl . carboxyl. and ester groups ofthc polymer back bone."lt 
is well known that 1,8-octanediol with long methylene chains shows a certain 
hydrophilicity. L-tartaric a<:id is hydrophi lic due to its two hydroxyl groups and two 
carboxylic groups, Furthemtore.the promising properties ofL-tartaric a<:i dasahackbone 
unit for building of polytartarate pol~'mers and their pot~."tial biomedical applications 
havebecnevaluatcd," 
Tile aliphatic polyesters. in gencral. do not havc the good physical and mee hanical 
properties required for many bioml..:lical applications. 19 Therefore. the goal is to modify 
the elastomers and to improve their mechanical and physical properties. by adding a 
erosslinking agent. to develop desirable elastomcrs for medical applications. To be 
considered for such applications. the elastomers must be biocompatible to avoid an 
inflammatory respon5e from tile hosttissllC and provide a suitable substmtc for cell 
atlachment and proliferation. 
Poly-(octanl..:liol-tartarnte) JlOSS"S3CS many advantages for use as an agent for 
controlled release for the following reasons: (i) It is compo$<,...:l of low cost monomers 
which increases the potential for future commercialization. (ii) It readilydcgradcs in 
biological systems via hydrolysis ofes\cr bonds toa non-to~icend-productsirn.:c neither 
the monomcrs nor the ems.linking agent used arc to~ic. (iii) The hydmphiliclhydrophobic 
(amphiphilic) properlies of the elastomers which are desirable in oomc biomedical 
appliClltions.20 can bc altcrcd by changing the ratio of llCP and length of the d iolchain.ln 
addition. the ability to roodify the dcgree of hydro phi Ii city oft he elasto mersfacilitatesthe 
use wi\h a wide range of drugs and pmleins. Thcreforc. the system can be railored to suit 
a specific situation. (iv) The poor physical strengths of the relatively low molecular 
weight elastomers can be tailored by modulating the BCP ratio. (v) Finally. the POT 
prepolymer has a low viscosity which facilita1los the injection and pourin g into molds at 
moderate temperature. Therefore. their design could be altered to achieve different 
mechanical pmpcrties and degradation rates by incorporation ofthc tetra-functional 
crosslinker BCP into the elastomer networb. 
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The synthesis. charactcrization. mechanical properties and in "ilro degradation of 
a novel s)'11thesized POT biodegradable elastomer arc reported in this study. This 
elastomer was prepared in two stages. The first involved Ihe preparntion of the aliphatic 
,hain of the POT prepolymer which is composed of two non-lOxic monomers: 1.8-
octancdiol and L-tartaric acid viaa rolye~terfication polymeri7.ation reaClion. The second 
stage involved Ihe reaction of a POT prepolymer wilh different ratios of 2,2-bis(c-
caprolactone-4-yl)-propanc (OCP) using stannous 2-cthylhcxanoatc as a catalyst. The idea 
behind using a BCP as a crosslinking agent for the preparation of biodegradable 
elastomers stems from tlte fact that ncp is hiocompmiblc wilh living tissues,ll and it 
increases the crosslinking densily of the e1aslomers. FurthemlOte. the influence oftbe 
molar ratio of BCP 10 POT used to prepare Ihe elastomers was examined 10 dClcnninc thc 
effect on their physical propertiessucb as mechanical behaviour. "''31erloss. sol content 
and. swelling degree. and 10 examine Ihe in "jim degradation of these elastomers by 
following the changes in thcir mechanical properties ""ith time. 
J.J MATERIALS ANI) l\I[nlOI)S 
The chemicals used in the synlhesis and purification of elastom<.'rS such as L-
tartaric acid and I.g-octanediol. stan!l(lllS octoate (SnOcI). acclone, chlorofoml. and elhyl 
elher '""'eTC obtained from Sigma·Aldrich. The chemicals used in the preparation of the 
crosslinker (BCr ) such as chromium triox ide, m-chloroperoxybenwic acid (mCPBA), 
acetone. and 2-heptanone were oblained from Sigma-Aldrich, and 2,2-bis(4-
hydroxycyclohexyl) propane was purl:hascd from TCI America. Other chemicals used 
such as 2-propatlOJ. dichloromdhane (DCM). glacial acetic acid. nod magnesium sulphate 
(MgSO.) were obmined from Fisher ScicmifLc Inc 
3.3.2 P,eparatian of 1:1 l'oly(Odancdiolc-L-Tartaric) PrepolJmtr (POT) 
Solvent free polymcrization was carried out in sealed silanized 20 ml ampoules 
L-tartaric acid and 1.8-octanc<lioi in 1: I molar l1IIios were transferred and mix~.,j into a 
dry ampoule. The ampoulc was placed in an ovcn al 160"C unti l complete melting Oflhe 
reactants. The mix was Ihen slirred using a vortex mixer. The ampoule was fi!1ed with 
nitrogen. name sealed under vacuum and placed in an oven again at 140 ·C for I hour. 
The prepared crude prepolymCr$ were purified by dissolution in chloroform. prcripitaled 
in cold anhydrous ethyl ether. and dried in V3cmlln ovemig.ht. The final product of the 
polyester prepolymer (POT) was disso lved in acetone-d., and was characterized using 
proton nuclear magndic reSOnanCe spectroscopy <'~I-NMR). mass spectroscopy (MS). 
fourier transfonn infrared (FT-IR) spcctromcny. differential seanning calorimetry (DSC), 
and gel pcnneation chromatography (GI'C). Scheme 3.1 sho ... -s a representalion of the 
synthesis ofpoly(ocmancdiol-tartarate) polyester prepolymer (pOn. 
I""" 4 H oY-n-0 ) OIt OH 0 n 
~
Scheme 3.1 
3.3.3 Pr~paratian a f Z,l· bis(c·caproiactane-4·y l).pr opsnc (HO') 
A detaikd synthesis procedure has been reported by Palmgrcn ct al." In summary. 
5.4gOlf2.2·bis(4·hydroxyhcxyi)propanc was dissolved in 29.5 ml glacial acelic acid tOl 
which a solution of5.5 g ofchrOlmium triOlxide in dilute acetic acid (25 mlofglacial 
acetic acid mixed with 40 ml distilled water) was added in a dropwisc fashiOln Olver a 
period Olf 2 hOlurs under stirring while maintaining a temperature of 17·18 "C. After th~ 
cOlmplete additiOln Olfthe reactanls, thesoiutiOln was 1eft tOl react fOlran()th~r30minutcs. 
andlhen25 ml Olf2·propanol wasaddedtoth~'Olluli()n. ThissoluliOln wascOlvcrcd wilh 
aluminiwn foil and left ovcrnight. Then this solution was uncovered and left under 
vacuwn for another ovemigilt t(}conccntratc. The conccntralcd solutiOln wasthcn poured 
intOl 200 ml Olf distilled watcr and a thick viOllet suspensiOln was fOlmled. The suspensiOln 
was filtered Ui;ing whatman nOl. I filter paper and the cake was washed scvcral limes with 
distilled water. The resulting white dicYc!Olhcxyi·4,4'-diOlnc (diketOlne) powder was dried 
in an Olvenat 50"C Olvemight andcharactcrizC<l. 
A I.\aeyer-Vill iger Olxidation reactiOln was then carried OUI Oln thc prepared 
dikctOlne as fOlllo\>,'S: In a round bottOlm flask, 3.9 g of mCPFlA, previou,I~' dried with 
MgSO,IOCM. was added in batches, about 12 batches wilh Olne hOlur between each balCh. 
to a DCM solutiOln Olfthe diketonc (4.lg in 200 ml) under reflux at 50"C and cOlntinuOlus 
stirring with a magnetic stirrer. The ';<JIUlion ",a, then len undcrthcsamccOlnditionsfor 
24 hOUTS. After the reactiOln was cOlmpleted. the solut iOln was filtered u~ing triple filter 
papers and the filtrate was left in the fume hood under vacuum tOl evaporate the DCM 
White crystal ~ of the Rep appearC<l after the eOlmplete evaporation of the DeM. The final 
product was purified and rc-crysmlli«,d with hot 2-hrptanone. Thc Enal ",·hite powder 
product ,,'as characterized using DSC and MS. S<;heme 3.2 summarizes the sleps invol~e<I 
inprcparing RCP 
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J.J.4 Syllth~. i s of the Elas tomers 
Bi , -Coprolacton< l'Topan«BCP) 
Several different elastomers of varying ratios of BCP (as reponed in Table 3.1) 
were synthesized. The following procedure describes the step. involved in preparing 
elastomer I using the weight ratio of POT to Bep as reponed in Table 3.1. In a dry glass 
ampoule, I g ofBCP was left in the oven for 5-10 minUles to dissolve at ISO"C. A mass 
of4 g of POT and an amount ofSnOet equivalent to 1.4 x 10'" mol for each I mol of the 
monomer were added to the ampoule. The contents were mixed using a ,·oncx mixer and 
the ampoule was sealed under ,·acuum. The ampoule was left in the vacuum Ovcn at 120 
·C for I hour and then the seal was broken and the highly viscous liquid was poured into 
rectangular Teflon moulds (100 x 6 x J mm), co'·cred. and left in the oVen at 120 ·C for 
,-------------------
18 hours. The elastomer was then removed from the mould and characteriz.ed lIsing DSC. 
jn ";Iro degradation and tensile mechankal testing. Table 3.1 li,IS the difkrent ratios of 
both POT and Bel' u=i I() prepare elastomers \-5 and scheme 3.3 summarizes the sleps 
involvC<linprcparinglheseelas\()mers 
Table J. 1 Ratios ofprcpolymcr (POT) and Bep used in preparing the elastomers 
S~mplc P""p"lymer (POT) Prepolymer (POT)mer 
(g) (g) 
Elastomer I 4.0 
Elaslomer2 5.3311.0 
4.0 0.50 
Elas\omer 4 16.0011.0 
ElastomerS 4.0 0.00 
~. 
o 
Sch~mc 3.3 
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33.5 Characterization of BCP and [Iastorne ..,. 
With the exception of the GPC. which is locatc"<l at the University of Alberta, all 
lXIuipmcnt uscd for spectroscopic characterizations were conducted and perfomed at 
Memorial University of Newfoundland 
Prolon·NMR of the prepolymer was run using acetone-d,; wilh a Bruk~r A VA NCE 
500Mllz Spectophotometer. The chemical shifts in p.1ns-per·million (ppm) for 'H-NMR 
spectra were referenced relative to tetramethylsilane (fMS. 0.00 ppm) as the internal 
reference 
To verify the identity of the product. mass spectrometry (MS) was carried out using an 
Agilent 1100 series LCiMSD system with atmospheric pressure chemical ionization 
(APCI) positive mode of ionization in flow injection mode. BCP sample was prepared by 
dissolution in OCM. Thc MS data was eolle<:tcd and analyzed using Bruker Daltonik and 
MSD Trap control Version 5.2 soft .... 'llre. 
GPC was perfomed using a I!ewlett-Packard 1100 system connected to a 
precision detc'Ctor (PD) 2000 dynantic laser scattering (DLS) light scattering dete<:tor 
suppl ied .... ith a Waters 410 differential refractometer. The mobile phase consisted of 
Ietl1lhydrofuran (ll·IF) at a flow rate of 2 mllmin with the system at a temperature of 
)s"C. The polymer concemration used was 2 mglml and the injection volwnc was 20 Ill. 
Monodisperse polystyrene standards were used for the initial calihnuion 
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FT·IR ~pe<:tra were obtained at room temperature using a Bru~er TENSOR 27 
Fouriertransfonn infrared spectrometer. Prepolymer .ample" werep"'""",..! by pouring 
over a zioclselenium crystal. IR data was analyzed using Opus Bruker Opti~ version 4.0 
software. 
The thermal prop"rtie$ of the elastomers and p",polymcr were charactcrized using 
DSC. The experiments were carried out on a Seiko 210 with cooling system machine. lbc 
sample (5-8 mg) wllS placed in an aluminium pan and " 'as run with a heating rate of 10°C 
Imin using a cycle from runbicntto -6O"C to I SO"C to -6{)"C to I SO°C. The glass Iransition 
temperature (Tg) was measured from the second heating cycle. The DSC instrument was 
calibrated using indium and gallium standards. The enthalpics. glass transition 
tcmpemtures, and melting cndotherm \-\'ere determined using the internal DSC analysis 
The sol ~'Ontent of the products and the swclling degree (R) of the corresponding 
gels \-\'ere measured in the following way, A small disc sample (3 mm in thickness and 10 
mm in diameter) with weight, WI. diamcter, DI and thickness. T1. was placed in 20 ml 
ofDCM for 24 h and was then taken out. The weight Qfthe disk was rc<:orded lIS W2 and 
the diameter as D2 and thickness, 1'2, afkr the solvent on the surface was absorbed by 
filter paper. The disk wllS dried to a constant " 'cight, W3, diameter. D3. and thickneSS, 
TI, in a vacuum oven at 40"C under 4000 I'a for 7 days. The sol contcnt wascalculatcd 
as follows: (Q) • [(W]·W3) I WI] X 100"10. Thc swelling degree (R) for the 
corresponding gel waS calculated as (R) = [(W2-W3) I W3] X 100% . Three samples were 
used f"rcaeh expcriment, and the average valucofthe three sarnplcs was reported 
The equilibrium water uptake in deioniLKd water is dcfined as the fraction of 
weight gained by the small disk sample and was calculated as water uptake - [(M2 -
MI )/ MI] X 100%, whereMI i,the initial weight oflhespcdmen and M2 is the weight 
of the sample aller it was placed in deionized water for 24 h. Three samples were tested 
for each product at room tempc,,-aturc and the average value was obta ined 
Tensile mechanical testing was conducted with an Instron model In-Spe<; 2200 
tester wilh Marlin rnA Data Managemcnt Sollwarc. TIle Instron was equipped wilh a 
500 newtons (N) lo.1d cell . The measurenlcnts of the mechanical properties of the 
elastomers were carried out on slabs (100 X 6 X 3 mm) using an t"stron with 
cxtcnsomcter. The extensorneter gauge length was set to 5 mm while the spe<;irnen gauge 
length was set to 30 mm. The cmsshead speed was set at 50 mm/min and the sample ratc 
'I\'as set at 0.833 mm/sec. Elastomers 1-5 (having various degree of cross linking), wcre 
tested at room temperature. A Young's modulus was calculated from the initial slope of 
the stress-strain curve. Three samples of each product were measured and the mean and 
standard dcviation were calculated 
3.3,6 In Vilro Dcgrncialio n Siudy 
Slab spe<;imens of elastomer~ 1 & 2 as listed in Table 3.1 were subje<.:\e<Jlo an 
pe>:elel""dted in vilro degradation study to demonstmlc the changes in mechanical 
properties during the degradation process. Each specimen was weighed and then p lac~-d 
into a \5 mltissue culture tube which was filled with 12 ml phosphate buITer saline (PBS) 
of pH - 7.4. The tubes \\'ere allachcd to a Glas-Col rugged culture rotator. The rotator 
was set at a rotation speed of 30 % and placed in an ov~n at 37 DC. The huITer was 
replaced every 2-3 da~'stoensure a constant pH of7.4during the whole period of study 
Samples of ciastomers 1 & 2 (each sample represents 3 specimens) were dried. weighed 
and subjected to tensile testing at time periods of O, 1. 2, 4. 6 and 8 weeks. Another set of 
samples of elastomers \-5 was lell without changing its butler. to monitor the change in 
the pH of the medium with respecl to time 
After the tensiletestins. the broken slabs werc collected and washed thrcetimes 
with deionized water and were then dried to a constant \\'eight (02) in a vacuum oven at 
40 DC under 4000 Pa. The mass loss was calculatc-d a~ follows: Mass loss - [(G I - G2) I 
GIl X 100 0/0. where 01 is the initial weight of the slab before incubation in the buffer. 
Three samples for each product Wel"<' tested at room Icmpernture to achieve the average 
value 
3.4 R):SUL TS AND DISCUSSION 
The aim of this study was to synthesize amorphous. biodegradable and 
biocompatible elastomers that would have a Tg 10\\'er than body and room tempemlures, 
and that would be utilized as a polymeric drug delivery system. especially for prolein 
drugs. To achieve this goal. the hydroxyl groups of 1.8-ocatanediol were reacted with 
carboxylic groups of L-tartaric acid in a I: I molar ratiQ using SnOct as a eatalysllo ronn 
polyester (octanediol-tarlaratc) prepolymer (I'On. Then. different ratio of Bel' were 
incorporated with the prepolymer to synthesize the biodegradable POT ciaslOmers. 
The IH_NMR spectrum of POT showed peaks at about 1.3. 1.5, and 1.7 ppm. 
which were assigned 10 the methylene protons. The peaks at 35 ppm call be altributed to 
the hydroxyl protons at the end ofthc diol monomer. The protons on the methylene group 
adjacent to the ester bond were attributed 10 Ihc peak at 4.2 ppm. and Ihc peak a t4.5ppm 
was assigned to the a-hydrogens on the L-tartarie acid as shown in Figure 3.1. A number 
avellige molecular weight of 1247 Daltons was estimated using the integrals of the 
chemical shifts of the IH NMR spectrum characteristic of the contributing monomers. 
The estimation was based on the degree of polymerization of bolh monomers. The '11-
NMR of the POT confirmed the composition as being 52.91 mol % 1.8-octanediol and 
47.09 mol % L-tanarie acid measured using the ratio of integrals at the chemical shift of 
1.3 ppm which com:sponds 10 the 1.8-octancdiol methylene proton resonances to that of 
4.5 ppm which corresponds to the L_tartaric acid mcthine proton resonances 
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Figure 3.1 IH_NMR of the prepared prepolymer POT. 
Mass spectrometry of the prcpared POT prepolymcr was perfonned to 
characterize thc fonnalion of the product and to confinn thc molecular weight . The 
resulting molecular weight was 1241 Da lton~. which agrees with the estimated molecular 
w-eightobtained using the 111_NMRspectrum 
The se«lnd step in the preparation of the elastomers was the synthesis and 
charactcritation of the tetra-functional erosslinking monomer BCP. 1lIc erosslinkcr was 
charactcrized by the APCI-MS spectroscopic method. The mass spectrum show" in 
Figure 3.2 confinncd the molecular \veight of the final product. A peak (base peak) 
com:sponding to the protonatL"<.I molecule (M+l) appears at mlz 269, which is consistent 
with the molecular mass of the expected DCP product. Thc prominent peaks observed at 
mlz 253.1 and mlz 239.1 are likely due to neutral losses of oxygen. [M-O+~lr, and 
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Figure 3.2 MassspeclrumofBCP. 
GPC molecular weight analysis of the prepared POT prcpolymer r<:$ulll..:i in a 
.... 'Cight average molecular weight of 1250 Daltons which is similar 10 the average 
molecular weight that was calculuted using lh~ integral of the chemical shifts of the 'H-
NMR spectrum and confirmed the previous molecular ,",-eight analysis results. 
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To confinn the fonnatio" of ester linkages in the backbone of the elastomers. n'-
IR was conducted. The spectrum of the POT prcpolymer is sh""n in Figure 3.3 , A 
rclatively sharp peak at 1734em·1 was found in the spectrum wh ich "1l.,attributed t()thc 
(C-o) of the ester group. The broad peak a\ 3443 em·1 was attributed to the hydroxyl 
groupslrctching vibrations and indicuting thut the hydroxyl group s are hydrogen 
bonded.11.14 Thenon_covalentintcr_andintra_moleeularinteraClions of hydrogen bonding 
and van der Waals attractive forces werc expected to enhance the thermal and m~"Chanical 
properties oftbe polycstcr. These bonds arc rclativcly weak and their role ist" maintain 
1000 cm-L was attributed to (CO) slrctehing. 
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Figure 3.3 FflR analysis of POT. 
DSC was used to investigate tlte thenna! properties of the prepared polymers. A 
DSC thennognun of the prepared POT prepolymer reponed thaI a semicrystalline 
prepolymer was prepared wilh a corresponding glass lransilion Icmpel1lture(fg)of-16. 2 
ec and melting temperature (Tm) of 51.2 "C. The heal of fusion oflheoorresponding 
endothcrm wasmeasurcd to be 36,39 JIg. 
The DSC analysis of each balch of dikelonc and BCP prepared and lested for 
purity produced sharp cndothennic peaks between 160-16S"C and 195·205°C, 
Tespe\:tively, as shoWll in figures 3.4 and 3.5. There were no olher inlcrferingendolhcnns , 
,,-hicltisanindicalionoflhcltighpurily lhalwasconfinncdwilhlheLC·MSdata. 
Figure 3.4 DSC Ihermogram of dike lone. 
Figure 3.5 DSC Ihem'ogram ofBCP 
Wilhlheslroclureoflhcprepolymcrandlhecrosslinkingagenlconfirrned.11le 
elastomers were prepared. The purified POT was crosslinked in different mlios with the 
Bep monomer. as lisled in Table 3.1. Fi~c different elastomers were prepared with 
different mechanical properties. A summary oflhe corresponding Tg. and Tm for each of 
lhe prepared elastomers is reported in Table 3.2. The data shows that all elastomeric 
networks ar~ Ih~rmosct amorphous polymcrs as no mclting tcmperatures were observed 
in the thennograms of any of tile prepared elastomers. Also. it shows that the higher the 
amount of BCI' u>cd in cro""linking the POT prepolym~"-. the higher the Tg of the 
elastomer. with a range from -to.lto -4 .8 0c. as would be expected due to the increase in 
the crosslinkingdensity of the elastomers 
Table 3.2 Thermal properties of the products 
Products Tg (0C) Tm rC) 
POTprepolymcr 57.2 
Elastomer 2 -6.1 
Elaslomcr3 -8.5 
EiaslOmer4 ·93 
-10.1 
II "ias noted thai in the presence of crosslin king agenl (BCP). the pol ymcrization 
lime was reduced from 36 hours. as in case of elastom~r 5. 10 18 hours. as in case of 
elastomers 1-4. On account of the differe~ in preparation (the absence of a crosslinkcr 
in case of elaslomer 5). only elastomers 1-4 were compared 
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II was observed lhal when a larger amounl of BCP is inlroduced 10 L-Ianarale and 
1.8-octandiol monomers to form polymers. (elastomers I & 2). it resulled in a highly 
crosslinked. amorphous network. On the other hand. elastomers 3 & 4. with a lesser 
amount of lIcr. consisted of soft robber-like segmenlS with lower Tg. The DSC results 
showed that Tg was directly proportional to the amount ofBCP used. The increase in Tg, 
upon the use ofa higher amount ofBCP. "as attributed to the restriction in the movement 
of the highlyerosslinked network of the polymer chain segmenLln other words. the 
higher the crosslinking density. Ihe bulkier thc segments of polymer and thegrcaterthe 
amounl of energy rc<juired 10 move it. Therefore. the Tg of Ihe highly crosslinked 
elastomers will rc<juirc a higher tcmperature than the 1esscrosslinked elastomers . 
S"'elii ng Proputie~, Structure of the Sol a nd Gd Products, and Water 
Uptake Studies: Swelling experiments On Ihe elaslomers showed that they eonsisted of 
crossl inked networks that conlained both insolublc parts (gcl) and solub1e pans (sol) (i.e. 
theponion of elastomer that had no covalent bonds to other chains in thc rn..1 work).ll\e 
con tent of sol was lower than gel and ranged from 2.16 10 9.76 % for elastomer I to 
elaslomer 4, respectively. The swelling test results showed relatively low sol content and 
elastomer nelwork formalion was confirmed,as none oflhe discs ofclaslomcrd issolved 
in dichloromethane, and each kept its original physical strocture after the removal of 
dichloromethane 
As shown in Table 3.3. the values of thc sol content % (Q) of elastomer I and 
elastomer 2 were the lowest. The values for Q of elastomer 3 and elastomer 4 were the 
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highest, which indicates that the gel content of these products " 'ere the lowest. Thegcl 
parts of the products grndually increased and the sol partsdecrellSt-od with the increase in 
the amount of BCP in the elastomers. Considering the mechanism of condensation 
polymerization and the preseno: of the tetra·functional crosslinking BCI>, these 
obser .. ations were expected. Upon increasing the amount of BCP of the reactants. more 
and more livingcrosslinkable tcnninals of the crosslinking agent in the chains were 
fomled. asaresuh,morecrosslinkingpoinlSweregenernK-d 
Table 3.3 Sol Contents, R, and Water Uptake of different elastomers in dichloromethane. 
Swelling dcg...,c ofthe 
Sui content 0/0 
): Ia, tomcr mrrfllpondinggel °;o Wateru l)(ake ~. 
,Q, 
(R, 
Elastomer I 2.16 161.45 2.22 
181.82 3.04 
Elastomer 3 6.59 249.43 3.31 
Elastomer 4 9.76 264.86 3.99 
The degree of swelling for the wrresponding gel (R) of the elastomers in 
dichloromethane is an important property forcharneterizing the dcgrcc of crosslin king of 
elastomers. Thc value of R is the total ofthcdcgree of swell ing of t he sol a ndgelpartsof 
thcpolymcrmatrix. 
From the R values ofthc ciastomers shown in Table 3.3. the following can be 
observcd.Firsl.allofthevaluesofthes ..... cllingpercentagcsrangedbetwcenl61 */0 and 
26S%,which implicd IMI the swellingreprcscnted by the the gei pan. was faidy high 
Se<:ond. the R values of the elastomers were the lowest with the highcst amount of BCP. 
elastomer I, and increase<! when the amount of BCP doxreascd; funhermore. R reached 
ils highest value when the elastomer had the least amount of BCr. elastomer 4 
By increasing the sol content Q. the swe ll ing degree R increases due to the 
swell ing of the sol pan. Therefore a high value for the swelling percentage means less 
crosslin~ing. in other words a lower gel OOnlenl. On the basis of such a model. the R 
value of the elastomers would be compose<! of both sol swe ll ing and gel swelling 
"Thereforc, the increase in the crosslinking density of the gel ponions was believed 10 
doxrease the R, the increases of the sol contcnt of the elastomers lead to an overall 
increase in R.n II was concluded tMt, increasing the amount ofBer within the elastomer 
nctworks would decrease the Q. and R values. and increasc the crosslinking degrceof the 
produets 
All the elastomers were insoluble in water. and swell~"<.l from 2.22 10 3.99 % after 
soaking in water for 24 hr. for elastomer I to elastomer 4. respectively (Table 3.3). The 
hydrophobicityofBCPinfluenccdtheextentof thewaleruptake. The water uptake of the 
elastomers was not high because water was prel'ented from diffusing into the materials 
due to the highly crosslinked structure. panicularly for elastomer 1 and elastomer 2. 
Water was able to diffuse loa gn:3terextcnl inclastomers 3 and 4 due to the lower 
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amount of crosslinking agent. In shan. the water uptake increased by decreasing the Bel' 
content: that is 10 say. decreasing lhe crosslinking densilyoflhe clastomers. ll 1lIe data 
confinned thaI by increasing the erosslinking density using BCI'. the sol conlenl and 
WlIter uplakc decrcases as a result of more anchoring lennini ofl3CI' molecules in the 
polymcrmalrices. 
Mttha nical Propcrtin: For the purpose of dctcnnining the medmnieal 
propeniesofe1aslomers 1-4. slabsoflhose elastomers wcre subjecled 10 tcnsik lesling as 
detailed in the experimental section of this WOrl:. All the claslomeric slabs Were 
completclyintactforlhetensiletestingand ..... ere'·eryeasytoaligninlhelnstronclamps. 
Figure 3.6 Sho\\'Slhe stress·strnin profiles foreiaSlomers prepared usingdifTcrenl 
BCP:I'OT ralios. Avemge values (for lriplel samples) for lhe Young'S modulus. E, 
extens;on mtio, 4. maximum Slress. o. and pen:enl slmin at maximum load. t. obtained 
for uniaxial tensile measurements are lisled in Table 3,4 
7J 
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Figure ) .6 Stress-strain bellaviourof Poly(Octancdio)·Tartaratc) POT elastomers. 
Table 3.4 Summary of the mechanical properties of the elastomers. Values arc means ± 
(standard deviation) 
Young's E:s lcnsio n 
Mu Slrcss "I. Stra in at i\1 ;u 
(J\ II'a ) (G) "o~d ( t) 
( I\I P~) (E) (4) 
Elastomer 1 0.23 :1: (0.01) 1.34 2,99*(0,02) 66.62±(J.87} 
Elaslomer2 O.lJ±(O.02) 1.95:1:(0.08) 80,85 ± (0.74) 
Elastomer 3 0.08 :1: (0.01) 1.78 1.48 :1: (0,01) 84.03 :1: (0.53) 
Q,05±(O.02) 2.04 1.05:1:(0.05) 95.27 :1: (0.71) 
The ciasticity moduli, E, decreased from a valuc of 0,23 MPa from elastomer Ito 
a value of 0.05 MI'a for elastomer 4. These results are mirmrcd in the results for 
maximum stress «(f). as the amount of BCI' decreased; the maximum stress also docrcased 
from a value of2.9910 1.05 Mla for elastomer Ito elastomer 4, respectively. A decrease 
in the amount of crosslinking agent resulled in the increase of the extension rdtio of 1.34 
for elastomer I to 2.04 for elaslomer 4. Similarily, the pereent strain al maximum load 
increased rrom 66.62 ror ela~tomer I to 95.27 for elastomer 4, Incorporation of higher 
amountsoftheCTOsslinker. IlCI',resultedin a tougher elastomer 
The stress-strain behaviours of all of the elastomers were a rencction of their 
corresponding Tgs. As cxp<.'Cled. incorporalion of higher amounts of the FlCP crosslinker 
resulted in a higher crosslinking density and tougher elastomer indicated by higher 
Young's modulus (El values and lower pereent slrain al maximum load (~) as for 
elastomer I. On the other hand. elastomer 4. with less IlCI', was a soft and weak 
elastomeric polymer with a low E and high &. Therefore. it can be concluded lhal a 
consistent correlation was establish~-d between the mechanical properties and lhe amount 
ofBCPadded to the polymer matrices. 
I n Vifro I>cgradation Studies: To detennine the changes in the mechanical 
properties and the degradation patterns of the prepared elastomers as a function of time. 
slab specimens of elastomers I & 2 were subjecled to an accelerated in vilrQ degradation 
experiment in PBS of pH - 7,4 at 37"C. Figure 3,7 shows the percentage mean increase 
in weight of the slab~ with respect 10 time Over a period of 8 weeks. The weighl gain of 
75 
elastomer I and elastomer 2 increased with time. due to the form ation of degmdation 
products that drew more water into the polymer matrix via o~mosi,. The reason for the 
increase in water eoment is likely due to the inability of the degradation products to 
di lTuseout from the bulk as a result of the high crosslinked density. Bytheendof8 
wecks.theela<tomericslabsbccamepaste·l ike intheirconsi,tencybulnoncoftheslabs 
had degraded completely_ The weight gain during the incubation of elastomer I and 
elastomer 2 resulted from water penetration into the amorphous network where it is less 
organized and more accessib le to water mol e~ules via diflusion,19 Such behaviour has 
bcenrcported forotherpol~'mers.].(I 
00 
r .... (Wooks1 
Figure 3.7 Percentage increase in weight of the tested slabs of the corresponding 
elastomers 
The hydrophiliciy of the elastomer is increased b~' the Fonnation offree carboxylic 
and hydroxylicend groups as 3 result of the nonenzymatic hydrolytic c1cavage of ester 
bonds during the degradation of the elastomer,)' Furthennorc. the hydrophilic moieties 
acted as a driving fOl\:c for imbibition of ,vater illto the elastomers due to osmotic 
activity. therefore the elastomers began to swell. Thus-the increase in weight of the 
elastomers with time can be uscd as a measurc of the rate ofdegrad3lion of the products 
This pal1em of degradation would result in the accumulation oflhe acidic monomers 
inside the bulk whichcontributcd to the further autocatalytic acidic d egradation. which is 
comparable to the degradation pattern of poly(DL.loctic-co-glycolic ocid) (PLGA) 
copolymer.)) 
It was reported that polymers containing both hydrophobic and hydrophi lic 
segmentsse<:m to have a higher biodegradability than those polymers containing either 
hydrophobic or hydrophilic segments only.3l>O POT elastomers containing a higher 
amount of BCP. which is hydrophobic, had a slower rme of degradation than those 
containing lower amounts of BCP. As such. we can conclude that the e!aswmeric 
properties can potentiaily be tailored by grafting hydrophobic moieties to the h ydroxyl 
groups. such as BCP, which inhibits the attack of the cster groups. The presence of both 
hydrophilic and hydrophobic segments provides the best charactcristics to the polymer 
during degradation and therefore. is very useful for the control!ed release of drugs.J! Such 
a pauem has been previously reported with many polymcrs. 16.J6..11 In general. the ratc of 
degradation increased with the increase of the hydrophilic moieties or de\:rease in the 
hydrophobic segments in the polymer chain.)' Increasing the crosslinking density in 
elastomer! o\'crelastomcr2servedloreducctheratcofhydrol}1icauackbyrestricting 
the segmental motion of the polymer chains and reducing the water penetration into the 
clastomernetwork 
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1l1e 11 % increase in weight during the first week indicates that degradation began 
immediately aller placement in the bulTer. This is likely because of the low molecular 
weight of the polymer. By the """000 w~"Ck. the absorption of water ,,'as higher in 
elastomer 2 than elastomer I. and this pattern continued for the eight wed incubation 
period. Thi~ behavior would be auribuk'<1to the lower crosslinking density of elastomer 2 
compared to elastomer 1. The higher the crosslinking density. the slower the degradation 
"'te.'~)9 
C hanges in the I\1cehanka l I'ropcrties during In Vitro Degradation: The 
de<.:rea.se in the modulus values for dastomer 1 and elastomer 2 during the in vilrO 
degrndation study reriod are ShO"l1 in FigurcJ.8. Adecrcase in the modulus with time 
during degradation has been reponed previously.11 This behavior is indicative of a 
homogenous bulk hydrolysis mechanism in which a random chain scission of eSler groups 
occurs along the backbone. 1l1e bond cleavage is occurring within the bulk matrix. 
causing a decrease in modulus as the number ofefTective elastic chains i s reduced with 
each bond cleavage. Similarly. the reTl:ent strain at maximum load. c. for clastomer I and 
elastomer 2 decreased until the second wttk and then maintained some elasticity ti lithe 
end of the incuhation period (data not shown). This is may be explained because 
elastomer 1 and elastomer 2 had elastic behavior due to thcirhigh crossli nkc'<1density 
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Figure 3.8 Change in Young's Modulus with time 
The changes in the uitimate tensi le stress, cr, of the dastomcrs during the in vilro 
degradaTion study were expected and were related to the other mechanical properties 
examined in this study, First, a decrease in the ultimmc tensile stress was ind icativc of the 
degl"~dation process of elastomer I and elastomer 2. In addition, the de<;rea>e in the 
ultimate tensi le ,tress was most significant aller two wceks of the illl'ilrO study and then 
declined more slowly unti l the values approached zcroby the end of the degradation 
study, (Figure 3.9) 
The mechanical properties testing was stopped at weck 6. The degraded slabs 
were vcry weak and hard to align properly in Ihe lnstronelamps 
, .... (Weeks) 
Figure 3.9 Change in ultimate tcru;ile stress tma)(lmum stress) with time. 
In general, polymer erosion can be classified into homogenous or bulk erosion. 
and heterogeneous or surface erosion.fO However. both types are extremes and the 
degradation mochanism ofpolymcrs is often characterized by a combinatio nofboth.ll io 
a previous study by Schliocker et aI., i\ was demonstrated that the degradation of a 
poly(diethyl tarurnte)--<.:o-{isoprop)·]jdcn tanarete) polymer mainly proceeds via bulk 
erosion. The polytartratc implant is characterized by a rnpid mass loss within a short 
period of time occuring after a definite lag pha.'II' without remarkable mass IOSS. 31 This 
behaviour is similar 10 the POT ela!ltomcrs. which showed a lag time of two weeks. 
(figurc3.1O). 
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Figure 3.10 Change in weight of the test~d elastomers with time after drying 
ll1c ehanges in the extension ra(io.4. for the ,labs with time arc rcported in Tuble 
3.5. Asexpccted. adecrcase in the 4 values accompanied the use ofa high er amount of 
BCPand the n:sulting higher crosslinked density 
Table 3.5 Summary of the changes in the extension mtio values with time for the tested 
slabs. Values are mean ± (standard dcviation). 
Elastome",T .. ted 
(Wcclu) ElastomH2 
1.34(0.05) 1.46 (OJJ6) 
1.30(0.03) 1.36(0.01) 
1.31(0.02) 1.45(0.05) 
1.37(0.02) 1.54(0.02) 
1.66(0.05) 1.67(0.05) 
During the first "iC1:k of tile study. tllerc was a decrease in tile extension ratio for 
both elstomcrs, which may be due to tile initial water uptake. After the first ",uk. the 4 
values increa.,.,d for both elastomers. Elastom~.,. I, the more highly crosslinked elastomer. 
had lower values than elastomer 2. Thi, behaviour is consistent with the m~"Chanical 
propertics tcstcd in the study. The loss of mechanical properties over the incubation 
period for elastomer I and elastomer 2 were directly related to the hydrophilicity of the 
material. The more hydnlphilic the material, the ea,ier it was to lose the mechanical 
properties.J • 
Since the crosslinked density is directly proportional to the stTCngth but inversely 
proportional to the degradation rate of POT elastomers. the properties of the elastomer 
"'eTC tailored by adjusting the amount of the crosslinking. Flexibility can be conferred on 
the elastomers by varying the amount of cros,l inker, The results show tliat POT 
elastomers are degradable copolymers and that the degradation rate Can be modu latcdby 
dtanging the ratio of Bep crosslinking agent. 
I'U Change! in the Ucgradatio n Media o.'c r Time: This experiment was 
camed out to monitor the change in pH during the degradation process, The medium was 
not ehanged during the "."hole testing period. there were no sink conditions, to assess 
whether there ,"ere any changes in the pH of the medium due 10 Ihe released products into 
the medium. As sho"'TI in Figure 3.11. the pH of the degr-.>dation solution decreased as Ihe 
degradation process proceeded, The appe"""",e of the dr-dslic pH changes with the 
different elastomers was parnllel with the obscrvable changes in the appearance of the 
elllStomers.attributabletoafa~terdegradationmtc 
Tino(dayI) 
Figure).11 Changeinpllofthedegradationmediawithtime 
In pal'1llld with an increase in watcr absorption. the pH vaiue of the degradation 
medium started to decrease. This is likely the result of the increase of monomers bearing 
the acidic carboxyl group ofL·tartaric acid in the medium. The hydrophilieity of the 
poiymerincreases due to the fonnation of free hydroxylic and carboxylic end g TOUps. As 
a consequence. the acidic monomer and oligomer products start to diffU5C into the 
surrounding medium and decrease the pH valuc 
Elastomers I & 2 showed the smallest pH change after it reached only a pH of ).5 
by day 10. Fortunately. END can survive stable and remains active wi thin this pH 
environment. and. sink conditions would be assumed in the human body. 
J.S CONCLUSIONS 
A series of novel biodegradable polyester elastomers "Iere successfull~ 
synthesized and characteriz."d. A crosslinking ngent, BCP, was u""d to change the 
crosslinking densities. swdling and the mc-chanical propenies of the elastomers. A 
consistent colTelation was established between the mechanical properties and the amount 
of BCP added into the pol~mcr matrices. The in vilro degradation study sho"'ed that the 
higher the amOUnT of BCP. the slower the degradation. The original mechanical properties 
were diminished with longer degradation times . The new elastomers follow a bulk 
hydrolysis degradation pattern and demon.~trate promising applications in tissue 
engineering and the development of implantable drugdelivel)' syste O1S 
1llc effect of the crosslinking dcnsit~ on elastomers by the addition of an external 
SOUI"I:C of crosslinking agent. BCP. was investigated. However. there are other factors that 
afTect the chal"~cteristics of elastomers. The uSC of different ratios of the monomers. with 
or without BCP can be investigated. Future experiments could be conducted to focus on 
the monitoring the molecular weight. the molecular weight distribution, the 
h~drophilicl1tydrophobic character. and thermal characterization of the elastomers during 
the in vilro degradation slUdy 
As a final observation. the elastomer crosslinking was performed under elevatL-d 
iCtttperature. which is not feasible for most drugs and cenainly not for protein drugs; 
Therefore. it was necessary to find a method that does not require high temperatures in 
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Chapter 4. Synthesis, Ch~racteril.ation and In Vitro Osmotic Release Studies of 
Pilocarpine Nitrate and Endosl~li n frnm 3 N~,.. Photo-crosslinked lIiodcgrad3hlc 
4.1 ABSTRACf 
I'u rpose: To prepare and characterize a novcl family of ultraviolet (UV) 
crosslink.ed bioocgradablc tJOl)-(octanediol -tartaratej (POT) elastomers and to test the 
effcctofdrug loading. particle size. dcvicegcomctry, and polymer properties on the in 
I'itro release of the water soluble drug. pilocarpine nitrate (PN) and endostatin (END) 
fmm these novel elastomers. 
Methods: An aliphatic polyester prrpolymer was first synthesized via the 
polycondensation reac!ion ofL-tartaricacid with 1.8-octanediol P( 140"(: for one hour 
under vacuum to form the POT prepolymer. The purified prepolymer was reacted 
stepwise with acryloy l chloride (ACRL) and the puri fi ed acrylated pol)-(octanediol-
tartarate) (APOT) prepolymer was then mixed with an UV initiator and subjected to UV 
light to form lhe pitolocurable elastomer. All the prepared products were characterized 
using proton nuclear magnetic resonance ('H-NMR) spectroscopy, fourier transform 
infrared speetromc(ry (FT-IR). and di lfcrcntia l scanning calorimetry (DSC). For in vitro 
release studies. PN powder of three different particle sizes was mixed "ith APOT to 
achieve a 10"/0 wlw loading. Lyophil ized END. with trehalose and bovine serum albumin 
(BSA). was mixed with APOT to achieve the same wlw loading. Each mix was poured 
into glass moulds and subjected to photo-crosslinking. PN prepared devices were 
9() 
immersed in scintillation vials with t~ three different media. END prepared devices were 
immersed in small scintillation vials containing phosphate buffer solution. Release of PN 
was dcteclt-d using UV analysi •. howewr. the END was quantified using a rhEND 
ELISA kit. The pereent releasc for both drugs was ploned versus time. 
Results: 'II-NM R and infrared analysis confinned the purity and structure of tile 
prcpolymer. Thcnnal analysis of the acrylated prepolymer reponed a semicr),slalline 
structure with acorrcspondinggiasslransiliontempcrature(Tg)of-1O.8"Candamclti ng 
cndothenn at S3.4"C. The final photo-crosslinked I'OT elastomers were amorphous and 
have a Tg of -4.4"C. The relcase profilcs showed that. contrary 10 reponed studies. 
devices fonnulatcd with Ihe same volumClric loading and smaller drug panicle size 
released drug faster than the devices with a larger panicle size. It was also shown that 
osmotic release contributed 10 t~ linear release panem of PN from the new POT 
elastomers. The elastomers also followed a bulk dcgrddation mechanism with no 
significanlwcightlossduringthcpcriodofsludy. 
Condusiuns: Novel biodegradable pho\o<rosslinked POT elastomers were 
successfully prepared and characterized,and are suilablc for implantablc sus tainedrelease 
delivery of hydrophilic drugs. 
4.2 INTROl)uc n ON 
The use ofbiodegl1ldable polymers in tissue engineering, "\ gene therapy6.1 and 
drug delivery systcmsl. '~ has inspired the dcsire to develop new biodegradable 
elastomcrs,'l·1J 11 is desirablc that biodegradable elastomcrs designed for such 
applications show a homogenous degrndation profile and keep theirdimen sional stabi lity 
during the drug release period 
One strategy to prepare elastomers involvcs the prcparation of pre polymers, then 
thennallycrosslinkingthoseprepolymersusingdifferentbiocompatiblccrosslinkers such 
as Rep 10 produce elastomers." However, the preparation involvcs the use of solvents, 
such as DCM or acetone, and elevatell temperatures, which would prevent it from being 
used as a delivcry vchicle for thcnno-sensit ;ve therapeutic agents such as proteins and 
honnones. 
In the previous chapter. the synthesis and characterization of thennoset 
amphiphilic elastomers as potential biomaterial for biomedical applkations was reported 
Bep was used \0 crosslink a semicrystallinc prepolymcr prepared by polymerizing L· 
tartaric acid with I ,8-octanediol and stannous 2_ethylhexanoatc as a catalyst. This method 
resulted in biocompatible biodegradable polyester elastomers. but a polymerization 
temperature of 120 "C was required in the thermal curing process. Such high temperatures 
would hinder the use of these preparellelastomcrs for delivering heat sensiti\'c protein 
drugs and honnonesthat denature at high temperatures 
In an attempt to enable the loading ofthermosensiti"e drugs into elastomeric 
matrices. photo-polymerization was used. Photo-polymerization has been utilized to 
synthesize biodegradable h)'drogcls and elastomers for se"cml biom~'<lical applications 
such as drug delivery systems. "·16 This technique involv~'<l the preparation of 
prepolymcrs with photosensitive termini which can undergo free radical polymerization 
and formation of photocu,,-'<.l elrustome", in the presence of a photoinitiator and ultraviolet 
(UV) light. This promising technique would present a number of bend its and advantages 
over thermal polymeri7.ation for the synthesis of biodegradable ellIStomers , First. it avoids 
the use of heat for the crosslinking process lIS it can be carried out at room temperature 
Sccond.thephotocuringprocessisrapidandprocecdsinamatlerof minutes. Third. it is 
a solvent-free process. Finally. the photocured el35tomers can be customized with 
different crosslinking densities and medanical properties by changing the number of 
photosensitive termini in the prepared acrylatcd prepolymers , Elastomers synthezied by 
this method would enable the iocorpomtion of heat labile drugs such as proteins. Thcre 
are many applications for photo-crosslinking elastomers in the biomedicallicld, 11.20 
EI35tomers can be used for the drug delivery of osmotically active and water_ 
soluble drug.~. It is well acccpkoJ that the osmotic activity of the drugs is a major 
componcntofthc drug release from such adevice ,ll,l l)l Many researche rs ha vefocused 
on thc different factors that affect the mode and the rate of release from those lIew 
delivery systems. ")1_1< It was demanstrnto:d that the osmotic activity. concentration. and 
the particle sizc ofthc therapeutic agents or excip ients. the degradation rat eafthe 
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polymcr.and the chardcteristie of surrounding mc<lia play important r<;tles thatafTectth~ 
releasepr<;ttilesofthebiodegmdablepolymericdevic~'S.I'.I1,2U"U; 
Volwnetrie loading plays an important r<;tle in the rclease of the drug fr<;tm an 
clastomeric monolith matrix. When the monolith system is loaM..! above the pcroolation 
threshold, that is \0 say. the drug particles dispersed in th~ polymer matrix arc 
interconnected with one another, the rcleaseofthe drug will not be controllable. Upon 
immersion of such a device into an aqu~'Ous mcdiwn. the water-fillc<l pores that arc 
fonned as water is imbibt.-d fr<;tmthe surface oftbe device replaces tbe active agent that 
leaches out into the medium and the release becomes non-constant and ditTusionaliy 
controliedH To control thc osmotic and constant rclease of the solutc from the de vice, the 
drug loading must be kept below thepcrcolation threshold, which isappr<;txi mutely 30 to 
35%.1),21,27 
Osmotically active drug release fr<;tm an e!astomenc device is outlined brieny in 
seheme 4.1. Stage I: By immersion of the drug loaded device into an aql>t'Ous medium. 
water vapour starts to difTusc into the elastomeric matrix and begins to disso lve thc highly 
osmotic encapsulated so lid drug particles. Stage 2: More disso)ution occurs and the drug 
capsules start to swell and exert an osmotic pressure on the surrounding elastomeric 
matrix. Stage 3: Microcracks are fonned due to the high osmotic pressure. and the 
dissolve<.l drug is forced out of the drug capsule. through the microcl1lcks in theelll5t orner 
into the rcleasing medium. This ruptures and microcracks process continues in a layer by 
layer fashion until complete degradation of the clastomer has t.>Ccurcd. 
~ . . . 
• =~=0.= lj ~ ? " i Releasing Medium 
Scheme 4.1 This diagram represents the stages of the osmolic release of one drug particle 
within the e1astomeric maIn", The particles close to the elastomer releasing mediwn 
interface will be releasro first. The process occurs in a scrial layer by layer fashion 
The release of a drug by an osmotic mechanism has several advantages; the two main 
advantages bcing that it provides a oontinuous release and the rate of release can be controlled 
by the manipulation of excipients. Additionally, the biodegradable polymers degrade into small 
biocompatible monomers and can be excreted via normal excretion processes in the body. 
thereby avoiding a surgical removal step. tn view of the challenges of administration of 
therapeutic doses of END, as described in chapler 2. the use of a biodegradable device having 
an osmotic release mechanism would circumvent many of the obstacles 10 the delivery of 
Implantable biodegradable polymeric devices would provide a unique practical means 
of localizing angiogenic inhibitors such as END at a twnor site. The strategy of using a 
polymeric controlled delivery device would reduce the amount of protein needed, relative to 
systemic administration, to achieve a similar angiogenic inhibition. However. fOT protein drugs, 
polym~orll have <lmg stability issues <luring polymer degradation bttausc of !he acidic moieties 
released which have an affed on the protein stability. 
Thrc.., ",ries ofcxpcrimcnts arc cics.cribcd in Ihiscil.1pler. Firsl. ciclailsoflhe synthesis. 
photocuring and charncterization of a novel biotlegradable elastomer is provided. This new· 
elastomer has potential fOT use as an implantable device for the deliwry of therapeutic agents 
and protein drugs. A series of photocurcd dstomcrs with varying amounts of aeryloyl chloride 
were prepared by means of the following steps. (i) Thennal synthesis of an aliphatic POT ester 
prepolymer using 2-ethylhexanoate as a catalyst; (ii) conversion of the tenninal hydroxyl 
groups to vinyl groups by an aerylation reaction; and (iii) phmocuring of the acrylated POT 
using 2.2-d imethoxy-2-phenyl -acetophenone (DMPA) as the photoinitiator. The resulting 
elastomers were characterized for structure and purit y. The photocurcd elastomer having 
optimal photO-<:TOsslinking was chosen for loading the therapeutic agents Pilocarpine Nitrate 
(PN) was used a.~a model drug in place of END, as END is vcry expensive 
Sewnd, the release profile of a highly osmotic agent such as PN from the novel 
elastomer was detemlined. In another experiment. PN was also co-fonnulated with trehalose. 
These experiments were designed to examine !he effects of osmotic activity. particle size of the 
drug. the device geometry and thc SUlTOun<ling media On thc rclcase profilc. 
Finally, an o,motic release study of END from the photocurcd elastomer was carried 
oul. END Iypholizcd particles were incorporated into the acrylated prepolymcr solution and the 
systcm was solidified into anelastomeric drug matrix by photocuring using ultrn-violct lighl. 
% 
Trehalose and BSA were Iyophiliz~d wirn rh.END 10 produce a homogenous mixture. The 
excipient~, trehalose and 13SA. were used to maintain the bioactivity of END during the photo-
crosslinking reaction. In addition. the END relcase was driven by the osmotic pressure 
genel1ltedbyth.::dissolvedtrehalo'ieco-lyph.olizcdwiti1.theEND 
In summary, this nOl'el elastomer which is biodegradable. ami has desirable amphiphilic 
propcrtics. is photo-crossl inked. and it is suitable to ddiver protein d rugs. Thefonnulationsof 
bern PN and END were altered by incorporation oflrchalose to increase the osmotic activity. 
The outcome was the developm~..,t of a new local drug deli\'ery system for a therapeutic 
protem 
4.3 MATERJALS ANI) METHODS 
L-tartaric acid and 1.8-octanediol and other chcmieals used in the synthesis and 
purification of elastomers including, stannous oclOate. acetone. aeryloyl chloride, 
triethylamine. and 4-dimeth.ylaminopyridinc. chloroform. ethyl ether. elhyl acetate, the 
long-wave UV (L WUV) initiator, 2,2_dimcthoxy_2_phenyl_a,etophenonc. piloc"'1linc 
nitrate salt (PN). (+) trehalose, and serum bovine albumin (BSA) were all obtained from 
Sigma-Aldrich (Canada). Recombinant human Endostatin and the ELISA kit were 
purehased from P~rproleeh Canada. and R&D Systems. respectively 
4.3.2 \'rcpantion or 1:1 \'oly(Oc tanediol.\..,.Tarta ric) Este r I'rcpolymer (I'OT) 
The detailed method of synthesis and characteri7..ation of non·acrylated 
prepolymers were reponed in Chapter 3. The schematic representation of the steps is 
repeated below 
1 0 ,,< ,,,yj Ho~O-L-"lOH 
~n 
Poty ..... prepolyrner 
Scheme 42 
4.3.3 S)'nthesis or th~ Acrylated rOT l'npol)'ntcr{A I'QT) 
Based on the number of hydroxyltcnninals in the POT prepolymcr. two moles of 
acryloyl chloride were used to react with onc mole of POT prepolymer to fonn APOT 
prepolymer. lhc synthesis is summarized as follows . In a three neck round bottom flask, 
20 gill of POT (0.016 mole) was dissolved in 200 ml of acetone on a magnetic stirrer 
using a magnetic stir bar. The flask was scaled using a rubber septum and flushed with 
argon gas. This step was repeated every 30 minutes. The flask was then immersed in an 
ice bath (if C). after which 10 mg of 4-dimethyl aminopyridinc (DMAP) were added as a 
catalyst. A stepwise addition of 0.032 mole of each of acryloyl chloride (ACRL) and 
triethylamine (rEA) were added over a period of 12 hours at (fe. The reaction was then 
continuednt room tcmperalurc for another 12 hours. The final solulion was filtered to 
remove the triethylamine hydrochloride salt fonned during the reaction. The polymer 
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solution WlIS concentrnl\."<l using a rotary ~"afXlrator and funhn purified via diswlu tion in 
chlorofonn. filtcred. precipitatcd in cold anhydrous ethyl ether. and thcn dried in the fume 
hood under vacuum for 2 days. 'J[_NMR. DSC. and FT-IR we", used to chamclerize the 
purity of Ihe final product and the disappearance of 011 groups as a result of Ihe 
fonnation ufthc vinyl groups at the ann tcnninals of the APOT prepolymer. 
4.3.4 Ult ra Violct-Cro!slinking of Ael)'latcd I'OT Prcpolymcr 
Thiny percent wcig/lt I volume (~.wlv) of 2,2-dimcthoxy-2-phenyl-acctophcnone 
(DMPA) in acetone WlIS prepared to fonn the UV initiator SOIUlion. In a small test tube. 
5011-1 of the UV initiat(!r solution waS added to 1 gm of acrylatcd POT. Tile viscous 
solution WlIS mixed well using a vonex mixer and poured into a cylindrical glass mould 
(6 mm diameter x 10 mm length). The sample was then exposed 10 UV lig/lt at a distance 
of 5 em at room temperUlure f(!r 5 minutes using a BLAK·RA Y long wave ultraviolet 
lamp model B·loo AP of 21.700 II-Wlcml relative intensity. The elastomer fonned was 
then removed fmm the mould. The crosslinked polymer was dried in the fume hood for 
one day to ensure complete evaporation of any remaining acetone and kept in the 
desiccator under vacuum until required for analysis and characterization. A schematic 
prescntation of the preparation process is ShOWll in scheme 4.3. 
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4.3.5I'oIJrncrCharaClcrizaitons 
Proton NMR of the acrylatoo POT wa, run in acetone-do u.ing a Brukcr 
A VANCE 500MHz Spectophotomctcr. The chemi~al shifts in parts-per-million (ppm) for 
the generated spe.;:tra were referenced relative to w!ramcthylsilane (TMS, 0.00 ppm) as 
Ihcintcrnalreference 
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Fourier transfonn infrared ("T-!R) spectra were obtained 31 room temperature 
using a Broker TENSOR 27 Fourier transfonn infrared spectrometcr. Thc acrylated POT 
prepolymcr samples wcre prepared and poured over a zindsclcnium crystal. The infrared 
data was ana!yze<! using Opus Broker Optik version 4.0 software. 
The thenna! properties of the elastomers and AI'OT prepolymers were 
characterized using a Seiko 210 DSe attached to a cooling system. The sample (5-8 mg) 
was placed in an aluminium pan and was run at the heating rale of 10 "C/min using two 
cycles. From ambient temperature to -6Qoe to 150·e to -6ife to IsO"e. with the glass 
transition temperature (Tg) was measured from the second heating cycle. The ose 
instrument was calibrated using indium and gallium standards. The enthalpies. glass 
transition temperatures. and melting endothenn were detennined using the internal DSe 
analysis program. 
4.3.6 Preparation (If Pilocarpine Nitrate (PI':) L.oaded Tahlets a nd Cylinde rs 
UV initiator solution (30"ft wtv ofDMPA in acetone. SOO Ill) was added to 10 gm 
of the APOT prepolymcr. The resulting viscous clear yellow solution ",'as mixed until 
homogenous. Three difTerent panicle sizes wcre prepared by sieving the PN powder 
through 45,100. and 300 Ilm meshes. A 10 percent weight I weight (% w/w) I'N loading 
was achieved by adding I gm of each particle size of the micronized po",uer to the mix. 
The thick suspension was then mixed using a vOI1ex mixer for I minute. The product was 
poured into glass moulds of 10 mm diameter x 3 mm length for the tablet moulds. and 
6mm diameter x 10 mm length for the cylinder moulds. The moulds were exposed to UV 
101 
light as previously described. The photo-<:rosslinked elastomers were then removed from 
the moulds by breaking and peeling the glass to get the final tablet and cy lindricaldcvices 
loaded with the PN salt Each device was weighed. When a 1:1 mix of PN and Trehalose 
were used to load the elastomcric monolithic systems. first both JXlwdcrs were dissolved 
in water to gct an intimately mixed solution. Water Wa, then removed using a Freeton ... 
model 77530 freeze dry"r, opcmting at -48"C and 36 X 10.3 mbar. The r<:.ulting powder 
Willi seived through a lOO)lm mesh sieve to obtain the final micronized mix. The drug 
content in all elastomcric tablet or cylinder deviccs was calculated based on HI% wlw 
which corresponds to approximately ]4.4 percent vol ume I volume (% v/v). which i. 
below the percolation threshold. HowevCT. % wlw is used as it is directly measured and % 
viv is calculated indircctly 
4.3.71 .. Vitro Release Stud )' ofPN and UV Anal)'s is 
The prepared monolith tablets and cylinders with different particle sizes (45 11m. 
loo)lm. and 3oo)lIll).10aded with 10"10 wlw PN ",·ith or withouttrehalosc were subje\:ted 
to in vitro release studies using pho~phate buffer saline (PBS) of pH 7.4 as a release 
medium. Furthermore. tablets and cylinders with ]OO)1lll particle size PN with 10"10 wfw 
were subje<.:ted 10 in vjlm release sludies using DW. PBS, and 3% NaCt as release media 
Three samples of each device were put into 40 ml amber scintillation vials filled with a 
pre-selected dissolution me<'! ium, The vials were attached to the Glas-Col rugge<'! culture 
rotator. The rotator was set at a 30"/ . rotation speed and placed in an Ol'en at J7"C. TIle 
release mediwn was replaced with fresh medium to ensure sink conditions and a constant 
osmOlic prcssur<: driving force. The release media were replaced over a period of24 days 
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or until a IOCl'% cumulative release was achieved. Solution' withdrawn were filtered and 
the concentrations were determine..! b)' an ultraviolet method of analysis at a maximum 
wavelength of 2 16 nm u,ing a MILTON ROY Spectronic 601 UVNIS 
spectrophotometer. 
4.3.8 L)' llholilation orl'rotcinwith Exeipients 
Iluman recombinant Endoslatin (rhEND) wa, co-lyophilized with trehalose and 
BSA. Trehalose and BSA at a ratio of 1:1 wlw were used. while the END amount 
remained 500 ng and to achieve a final amount of 10 % wlw in each device. Tv prepare 
the Iyopholizcd protein. the excipient was added as a solid to aliquots of the protein 
solution and stirred gently at room temperature unti l dissolution was complete, The 
solution was then filtered with II 0.22 )1m I"w protein binding filter to remOVe any 
particulate. The filtered solution was subjcctcd to a cycle of freeze drying at-48OC and 
36 X 10-) mbar for 36 hours to ohtain the lyophilized product. The lyophilized product 
was ground inlO powder using a mortar and pestlc and sieved througll a 220)lI11 to 300j.!ll1 
4.3.9 PreparatioD ofrrotcin LoadedElastomcrSlah .• 
Lyophilized powder was mixed wilh a polymer comaining the photo initiator (0.25 
15m of APOT prepolymer + 12.5)11 of300/0 wlv of2.2-dimethoxy-2-phenyl-acctophenonc 
in acetone). This suspension was poured inlo Teflon I"C\:tangular moulds of 6mm X 5 mOl 
x 1.5 mm. and then exposed to UV radiation for 5 minutes to crosslink the prepolymer, 
After crosslinking, the drug loaded slabs were removed from Ihe moulds and dried in the 
fume hood overnight. The drug contcnt in each elastomeri" slab was calculated based on 
10"/0 wlw (coITCsponding 10 an approximate 14.4% v/v) to ensure that the loading was 
well below the polymer pcrcolation threshold of30-35% 
4.3.10 In Vitro Rdc,""c Siudy a nd Qu~nlitative Anal)'sis of the I'roldn 
The release study was carried out b~' immersing the protein loaded elastomeric 
slabs in small scintillation vials containing 2 ml sterile PBS with pH = 7.4. The vials were 
attached to the Glas-Col rogged culture rulator. The rotalO[ was set at a 30"/0 rotation 
speed and placed in an oven at 37 "C. The relca~ medium was removed at pre-
detennined time intervals and replaced witn fresh buffer to enSure sink oonditions and 
constant osmotieprcssuredrivingfor<:e.Thecollededsampleswercdivided into aliquots. 
andfro7.enat·SO"CforsubscqucntanaiysisofeoncentrationusingarhENDELISA kit 
PN'pantion and Characterization of a Photocured Elastomer: rhe aliphatic 
polyester POT prcpolymer with two hydroxyl groups at the tcnninals was prepared using 
so lvent free polymeri7.ation of 1.8...:x:tancdiol and L-tanaric acid nt 140"Cinthepresenceof2-
ethylhexanoateas acatalys!. Thcfull synthesis procedure andcharactcrization was reported in 
chapter 3. 
Thephoto-polymeri7.3.tion reactions ,",'Cre eonductcd with different ph oto-polymeri7.able 
end groups for the purpose of UV_pholO_crossli nking_11.29 The acrylation mcth od "illS selected 
because it possesscs a high reactivity with photo-polymerization conducted in the order of 
minutes.lt Moreover. the final da.tomcrs degrade into acrylic acid which is extensively 
metabolized into water solublc end produel5 that are safely washed out andexcreled by the 
kidney without bioaccumulation.lO For these unique properties. the tenninal hydroxyl groups in 
the previoU5ly prepared I'OT were suhjected 10 an acrylation process'l.2·.u using acryloyl 
chloride for the purpose ofrepladng the OI! groups at the lermina! oflhea!i phaticPOTchains 
with unsaturated vinyl tenninals. These acrylatcd temlinals can undergo crosslinking via UV 
pholo-polymerization Icclmology in the presence ofDMPA as a photoinitiator. 
In order to optimize the amounts of acryloyl chloride required to undergo the complete 
aerylation process of the hydroxyl group tenninals of the POT prepolymer, different molar 
ralios of acryloyl chloride were reacted with the POT prepolymff as shown in Table 4.1. 
Table 4.1 Acrylated POT synthesized by using different amount of aCly!oyl chloride to react 
with POT prepolymer. 
Acrylated POT Cooe POT (mol) I Acr}'lo}'l chloride (mol) 
POT-O.O 
POT-O.S 1.0 / 0.5 
1.011.0 
POT·2.0 1.012.0 
rhe VT-IR spectra for the acrylated prepolymers are shown in Figure 4.1. [I is 
clear that by increasing the molar ratio of the aeryloyl chloride to POT. Ihe intensity of 
the COlTesponding OH stretching at (3500) em" decreased with concomitant increase in 
lOS 
the fonnation of vinyl group t<:nninal5 which are indicated by the appearance of the new 
C..cstl"<!tchingpeakat(1690)cm-' 
Figure 4.1 FT·IR Sp<.."(:\m of the acrylated POT prepolymers reilCted with diffen.'Tlt molar 
ratiosofacryloylchloride. 
FT-IR spectra showed tllat the complete disappearance of the OH stretching was 
taking place with acrylated POT-2.0 compared to the OH stretching peak in the case of 
non-acrylat~d POT-O,O. This ob"'f\'ation can be observed more clearly in Figure 4.2 
Figure 4.2 Ff-IR spectra of POT before and after acrylation process. 
llte eruculatcd conversion perecntagcofthe hydrox)'l groups to thc corrcspondin g 
vinylgroupsweremeasuredusingthefol]owingequation:J ' 
[[l AU",) 1 J AUP, _" , %Conversion - 100- [AUP'Iff )".r xlOO 
AUP(".() "'" 
Where AUPoHis the arCa und~r the peak of tile OH strelching at (3500) cm·! and AUPc-o 
is the area underthc peak for CEO stretehingat(1734) cm-' 
As shown in tahle 4.2,there was no significant dilTcrencc bctween thecalcul alcd 
percentage of conversion comparcd to the theoretical values. In general. it was obvious 
that the optimwn amounts ofaerylo)'1 chloride used for the acrylation of POT prcpolymcr 
was one mol of aeryloyl chloride to one mol ofOH in the polyester POT prepolymer and 
resuhcdinaconversionpercentageof96 ~. 
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Table 4.2 Area under the peal:: for OH and C=O stretching for POT and ;l\:ryiatoo f'OT 
and % conversion oflhc tenninal hydroxyl to the vinyl groups. 
Acry lated AUP AUP(OH) / Tlleoretical ~. 
pre polymer (O U) (C" O) AUf (C"()) Connrsion ConHrsion 
POT-O.O 4651 4588 1.017 
POT·0.5 3452 
The acryl3lion process and furthcr purification was confinncd using 'H-NMR 
spe<:lroscopy. The acry!ated groups were represented by the peaks of aery] protons 
bct\\'Ccn 5.9 and 6.] ppm for OCHC~Hl (cis). and 6.4 and 6.5 ppm for OCHC~Clh 
(rrans) as sllownin Figure 4.3 
Figure4J 'H-NMR of the acrylated POTprepolymcr 
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The thermal analysis of the aCI)'lated POT prepolymer using DSC demonstrated a 
scmicrystalline structure with a melting endotherm at 53.4"C and with a glass transition 
(fg) of -IO.S"C. However. the I'OT-2.0 elastomer showed that il has no mehing 
endotherm. indicating that the final product was an amorphous pootOSCI elastomer with a 
Tg of -4.4"C, which is well below body temperature 
The pooto-crosslinking process was initiated using DMPA as a pootoinitiator. 
DMPAwaschoscnbccauscitpossessesmanydesirablepropcrties. ltisahighlyreactive 
photoinitiator which accdcrutes the crosslinking reaction. It isbiocompa tible and has low 
toxicity on living tissues. It has good initiation efficiency and a low amount ofunrea<:ted 
initiator remains in the photocured polymer.JlJJ 
Photocured elastomers W~'fe produced after 5 minutes of exposure oflhe acrylated 
POT prepolymer to L WUV light at a distance of 5 cm. The polymerization .... 'lIS rapid, the 
crosslinked network had formed and was confirmed by immersion of the elastomers in 
DCM. The elastomers swelled, but did not dissolve. This Ix<haviour can Ix< us.cd as an 
indicationlhatcrosslinkingliasoccurrcd 
The elastomer with the highest amount of crosslinking (POT-2) was us.cd for the 
drug release studies, as all the hydroxyl groups were converted to photosensitive termini, 
andthcreforc would provide the highest degrce oferosslinkingdensity 
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l)rug Release Studies: The original purpose of the proj~"<.:t was to load the 
angiogenic inhibitor protein. END. into a novel biodegradable elastomeric polymer at a 
volumetric loading well below the pt'l'l:olation threshold and to achievc a prolonged. 
sustained, and osmotic release of the END. The inlcnsion was 10 dClennine Ihe conditions 
for the developmcnl ofan oplimal release profile by monitoring the effeclo ffactorslhat 
govern the release such as panicle size. surrounding medium. device geometry, and the 
osmolic activity of the incorporntcd excipients with the protein. For economic reasons, 
Ihis dctenninat ion was initial ly carried out using Pilocarpine Nitrate salt (PN) as a 
peptidomimetic. hydrophi lic. water soluble and thernpeutic drug. When thc optimal 
conditions were determined. the END Qsmotic release study "'<IS carried out 
PN was selccled because it is a peplidomimelic drug wilh rcawnablc osmotic 
activity. the conccntrntion in the releasing media can easily be measured using UV 
analysis. and it is an inexpensivc drug. The stability of PN in thc three used mcdia. PBS. 
DW. and 3 ~. Nnel. was tesled and showed no significant changes during a one-week 
period 
The goal was to develop an osmotically controlled drug release system. [so-
osmotic (PBS), hypo-Qsmotie (OW) and hyperosmotic (3% NaCl) releasing media were 
used to delermine the degree of osmotically CQn1rolled release Qf drug from the elastomer 
The osmolalities of these releasing media. as well as f'N and the excipient trehalose are 
reponed inlllble4.3 
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Table 4.3. Osmolality of PN solution alld release media.) 1 
Osmolali.,.· 
(mOsmlkg) 
DcionizcdWatcr 20 
PhosphateBurTcrSaline(PBSjofpH- 7.4 
919 
Saturated Pilocarpine Nitrate 
Trehalose 1524 
Influence of Particle size on drug rcIeD~e: Figures 4.4 and 4.5 show the release 
pmfilesofPNofdifferentparticicsilcs.45.IOO.and300ilffi,respectiveiy,fromtabular 
and cylindrical devices in PElS media. It was noted that the release profi les consist of 
three distinct regions. A pR-dorninant burst r.:lease which lasted for the first 24 hours 
accounting for 40% release of the loaded drug . This portion resulted from the drug 
particicsdispcrsed at or close to the surface of the devices, The burst amount in the two 
devices "'lIS almost the same. This ini tial burst segment was simi lar to many 
biodegradable polymers.,H' The initial burst release was followed by a slower sustained 
and constant release pcriod that lasted up to 10 days. This constant release scgmcnt is due 
to both dilrusion and osmotic phasc and accounted for 30-40% re lease of PN, Thcfurthcr 
increase in the releascf3tc was due to the degradation oftheeiastomers. 
-~ 
Figure 4.4 Cumulative percent PN released from 10 % wi", loaded tablet devices with 
different particle SilCS in PBS medium at J7"C 
l1lc high release during the first and Sl'<:ond phase oflhe release profiles can be 
auributed 10 the hydrophilicity of both tile polymeric ndwork and the PN salt. 11 should 
be nOled that these experiments were performed under highly-accelerated in l'ilro 
dcgradalionproccsscslhalincrcasedthehighdcgradalionl'1lteofthesehydrophilic 
Figure 4.5 Cwnulative percent PN released from 10 % wlw loaded cylinder devices with 
different panicle sizes in PBS medium at)7"C 
The release profiles of the devices fonnulated with the same volumetric loading 
but with smaller drug panicle sizes I'l:leased drug fa~ter than those devices with larger 
particlesi7.cs. Thi'phenomenon canbc attributed to the facltltatlhc:;mall particlesizcs 
dissolve more rapidly and require less waler vapour 10 rupture the capsules. Funhennore, 
the shoner disllllCes belween lhe drug panicle la)'crs would lead 10 a shorter time to 
rupture the encapsulated drug particles wilhin the elaslomeric matrix. As shown in 
Figures 4.4 and 4.5, Ihere was no significam difference between Ihe release profiles of the 
tabular and cylindrical devices. Clearly, the device gcometry did not play a rnaj orroJein 
lhereleaseofthePN. 
11) 
Innuenee of Osmolality of thc Reicasing Media on ])rug Release; The effect of 
the release media on the relcascrate of the tabular and cylindrical network is shown in 
Figures 4.6 and 4.7 ",specti~ely , It was noted for the three different dissolution media that 
the constant release phases started from day 2 up to day 10 for bolllthc tabular and 
cylindrical devices and were within Ih~ same range. This indicates that one relcase 
mechanism is controlling the release of PN from thc these networks, regardless of the 
releasernediumusOO. 
Figure 4.6 Cwnulativc perccnl PN released from 10 % wlw loaded tablet devices of 
lOOfIrn particle size in different osmotic media 31 37 "C. 
Figure 4.7 Cumulative percent PN released fmm 10 % wlw loaded eyl inder devke~ of 
IOO)lm panicle size in different osmotie media at 37 "C. 
The osmotie activity oflhe NaCI m~-dia (919 mOsmollKg). is higher Ihan that ofa 
saturated PN solution (791 mOsmoI/Kg). No osmolie release occurs under Ihese 
eonditions. The profile of drug release in 3% NnC] is due 10 the degradation of the 
elastomer. The increase in the amOunt of the drug released into the PBS medium is due to 
an osmotic effc.:t. as the osmOlie activity of the PBS medium (280 mOsmollKg) is lower 
than that of saturated PN solution. Even more drog Willj released when the the medium 
was deionized water 
"The predominant mc.:hanism of drug release was degradation with an additional 
osmotic effeet when the releasing medium had a lower osmolality than a saturated PN 
solution. The osmotic cffc.:t when Ihe releasing medium was PBS was more clearly seen 
liS 
in the tablet than the cylinder. This difference might be attributed to differences in the 
surface areaofthc twodcviccs. 
One of the successful strategies utilized to maintain the stability and activity or 
therapeutic protein, is to coformulate th~m with stabili7.ingagen15 such as trehalose l\Ild 
mannitol. l• Such a strategy would offer protection to the protein from aggregation. PN. as 
a model for a protein drug, \\'as formulated with trehalose 10 study the effect oflhis 
osmotically active agent on the release rate . Two polymeric devices with tabular and 
cylindrical geometries wcre loaded .... ith a I: I ratio of trehalose and PN with a total 
weight fruclion of 10"/. wlw with a lOO)lm particle si7.e 
figurcs4. 8 and 4.9 show therdcasc profiles from tabular and cylindric al devices 
in PBS at pH ~ 7.4. The addilion of the high osmotic excipient . trehalose, resulted in an 
increased release mte in all phases. More than 50% "'as released in the initial burst, 
"i tllin the first day, "ith the balance of the 85~. total re lease being released \\ithin 5 
days. The increase in the releaseofPN "'as greater in the tablet than the cylinder. 
Figure 4.S. Cumulative percent PN released fr(>m 10 % wiw loaded tablets of l00).Ull 
panicie size with Or without trchalose in PBS medium at 37 "C. 
~- ­--0- PNonIy 
Time tv 
Figure 4.9. Cumulative percent PN released from 10 ~. w/w loaded cylinder:; of 1(0).Ull 
panicie size ,,;th or without trehalose in PBS medium at 37 "C. 
lIased on the above obser.·otions, it is evident that the osmotic relea semechanism 
plays a role in the release kinetics of PN since the incorporation of the highly osmotic 
release agent. trehalose. increased the amount of drug in the tabular device until all the 
drug that was loaded was released. There ..... as no significant additional release of drug in 
the prcsenccoftrchalose in the cylinders 
Release of rhEND from the Elastomer .'ormed from POT-2: The above 
experiments were carried out to estab lish the conditions for the release of END from the 
elastomer. The main problem in the incorporation of proteins in a polymer delivery 
device is the protcin aggregation that occurs during the loading step . Excipicntswcre used 
in the formulation to prevent such aprobiem 
Trehalose was shown to he a good stabili~r of proteins," and. as was shown 
above. increased the release of a peptidomimctie drug from the elastomer. It was expected 
that trehalose would act to stabilize END and increase the amount of END released from 
the polymer. 
Ilovine serum albumin (I3SA) was also shown to he 8 powerful Iyoprotoctant for 
proteins. This effect is attributed to its role in the inhibition of the pH drop that occurs 
during lyophi lization in a buffer and inhibition of the protein adsorption to the surface.)' 
In addition. it would prot~t the protein from the acidic monomers formed from the 
degraded polymerw;thin the rcleasingmedium. Therefore, lyophilization in the prescnce 
of trehalose and BSA would provide the best prot~tion for END during the device 
preparation and the protection would extend during the release in the relcasing medium 
In addition these two excipicnts "'ould block the exposure of END to the gellCration of 
fre.. mdicals in the solution and to UV radiation during photo-crosslinking. 
! I I I I 1 I I 
T,me (houl$) 
Figure 4.10. Cumulati~e amount ofrhEND released from 10"/0 wlw loaded slabs in PBS 
medium from a slab at 37 "C detected using ELISA assay from stored frozen aliqoots. 
Values are mean ± (standard deviation) 
figure 4.10 shows the release profile for rhEND from a slab of the elastomer in 
PBS. The slabs were used in thi s experiment instead of the tablets because of economic 
considerations. The release profile consists of three distinct phases. The initial burst 
release segment occurred during the first 9 hOllT5 of the release study and accounted for 
30% of the release of END. This initial phase was followed by a slower. linear. constant, 
and sustained release for 5 days and accounted for an additional 20% of the release of the 
drug. Finally, the last release segment of the profile was attribut~-d to polymer degradation 
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and WlIS extended for anotllcr week until the remainder of the drug par1icles were 
The release profile was distinctly different from that of PN. Thc difference might 
be due to the presence ofl.lSA or the geometry of the delivery system since the slabs were 
smaller and thinner. Also. the two drugs were different, one was a ~ptidomimctic drug 
and the other waS a protein. Further experiments would need to be carried out to 
detenninc the reasons for thediffcrences. 
A solvent free polymerization \\'as carried out using a 1:1 ratioofL-tartaric and 
1.8-octanediol to produce II polyester POT prepolymer, The acrylation reaction \\'as 
started by adding different ratios of ACRL 10 convert the terminal OH groups into 
photosensitive vinyl termini. Higher amounts of ACRL used in the reaction resulted in an 
increase in the percentageconvcrsion with an approximate complete convcrsionachieved 
when 2 moles of ACRL were used to relIct with I mole of POT prcpol)mcr 
A release study ofPN (10% wlw loading) from mOI\Qlithic tablets and cylinders of 
the prepared photocured elastomers was carried out. The release profiles were divided 
into three release phases in which the second linear release phase was a mix of osmotic 
rdease and diffusion but mainly dominated by a degradation medanism which was 
obvious during the last phase of the release . The relea.<;c profile was unchanged when PN 
was co-formulated with trehalose. but more drug was released. Upon using this excipient, 
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a larger fractionofPN was released during the initial burst phase. th<:n lhc release becamc 
li"",ar until complete I'N release was ltI:hieved. In this situation. osmotic release 
contributed todrog release. Our results show that smaller panicle Si7.o:S arerelcased more 
mpidlyfrom photocun:ddevicesascompan:<l to drugpanic1esoflarger sizes. In ad dition, 
the osmolality of the releasing medium has an effe<:t on the release mle. howe\'eT. 
geometrically dilTerent designs do not play a significant role on the releascofPN from 
thcsctwodilTerentdevices. 
Thcobjcctive of this study was to use th<: photocured elastomer for th<: delivery of 
END. The study demonstmled that the devke has a potential to be utilized in delivery of 
END in constant and sustained release fashion, but only for a short period of time 
Therefore, continuation of this work would be to extend the time period of release by 
incorpomlionofhydrophobicoligomerstodccreasethedegradationmtcoflhepolymer, 
while maintaining the elTcct of the excipienlson the activity and stabi lily of END 
This novel biodegradab1e elastomcric drug delivery vehicle can be considered a 
potential drug delivery device for proteins other than END. Funherstudicsconcentrated 
with END activity, confonnational changes and possible denaturation and aggregation of 
thc END paniculates are required 
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Chapter S. 
5.1 Summary 
The main objccti~'e was to emphasize the need to design a ncw 10000al delivery 
system to produce a sustained reiea'le of END within the therapeutic window oflhe drug 
Initial steps towards this goal have been achieved by incorporating END ,,-jth other 
osmotic excipicnts as solid panieles imo a photocured elastomer which allowed the 
protein to release at a controllable IlIte imoa localized area. 
Goal: The review of the literature focused on the evaluation of the different drug 
delivery systems and the routes of administration for END. as a therapeutic protein for 
canCer treatment. Long tenn. site localized and sustained release of END is a very 
desirable goal in order to maximize the therapeutic outcome of the drug and at the same 
time to minimize the side effects due to the exposure of the othcr body pans to the 
inhibitory cffcct of this powerful angiogenesis inhibitor. 
Thermnl Preparation of t~laston'cl":'! and Characterization: A solvent free 
polymerization of 1:1 L-tartaric acid and 1.8-o<:1anediol to fonn a scmicrystaJl ine POT 
prepolymer ",as carried out. The reactive prepolym~'1" that was fomled was thennal1y 
crosslinked with different ratios of 2.2-bis(&-caprolactonc-yl)-propanc (Bep) using 
stannous octanoatc (SnOet) as a catalyst to prepare crosslinked elastomers. All the 
po lymer products were thennall)', chcmically. and mechanically characterized 
Accelerated in "jlm degrndation studies were conducted. These studies demonstlllted a 
direct cOlTelation between the loss ofmeehanical properti e~ with time, and confinn~-d tlmt 
bul~ hydrolysis was the predominant mechanism of polymer degradation. As a final 
observation, the elastomer erosslinking was traditionally perfonned under elevated 
temperature. which is not feasible for most drugs and certainly oot for protein drugs: 
thcrcforc, it was necesS3ry to find a method that does not rcquirc high tcmpemtu res in the 
preparation ofthc elastomer. It was decided to dcvclopa non-thermal and photocuring 
method to prepare a photO-CrQSslin~ed elastomer to be used for delivery of END 
l'hoto-cr055 linkcd I'rcpar ati(ln (If t)ut(lmCI1I and Ilrug RclcQ5e Studi es: An 
aliphatic polyestcr prepolymer was synthesized via a polyeondensation reaction of 1.-
tartaric acid with 1.8-octanediol to form a POT semierystalline prepolymer. The purified 
prepolymer was reacted stepwise with acryloyl chloride (ACRL) and the purified 
ocrylated poly(octanediol-tartarate) (APOT) prepolymer was then mixed with a UV 
initiator and subjected to UV light to form the amorphous photocurable elastomer. For in 
virro release studies, PN powder of three different particle si7~s was mixed with APOT to 
achieve a 10"10 "11"1 (approximately a 14.4% vlv) loading. Lyophilized END with 
trehalose and bovine serum albumin (BSA) was also mixed with APOT to ochieve the 
same volumetric loading. Prepared devices were used to conduct release studies. The 
release profiles showed that dcvices formulated with the same volumetric loading and 
smaller drug paniele size released drug more rapidly than the devices with a larger 
panicle 5i7.\:. It was also showTI thai osmotic release waS a contributing mechanism 
governing the linear release pattern of PN from the new POT elastomel"5. The study 
demonstrated that the device has a potential to be utilized in the delivery of END or any 
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other hydrophilic protein drug in a constant and sustained release fashion. but only fora 
shon period oflimc. Further modifications to the elastomer will be required to extend the 
pcriod of sustained relca>;e. Using different ratiosofL·tartaric with 1.8-octancdiolandlor 
changing the photosensitive termini of the prcpolymer may change the crosslinking 
density. That may ,low the degradation process and i n~rease the period of the drug 
release 




